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ABSTRACT 
 
Multiple sclerosis (MS) is a neurological disease of the central nervous system which causes the 
nerves to deteriorate over time. MS affects individuals between the ages of 20 to 45 years of age 
and both biological and environmental factors are associated with the disease. Canada has one of 
the highest rates of MS in the world along with several European countries. The definitive cause 
and cure for MS had not been determined and because of this the quality of life of people living 
with MS is poor. This thesis investigates the following topics: population awareness about 
second hand smoke exposure and its association with MS; the importance of having social 
support and its effect on managing pain in MS; medication use; and the effectiveness of exercise 
in improving the physical, mental and social quality of life of people living with MS.  
The analysis shows that there was a lack of knowledge in second hand smoke exposure and risk 
of MS development in the Canadian population. Individual responses in agreeing or disagreeing 
to whether second hand smoke exposure was a risk factor for MS varied based on the provinces 
in which respondents resided, demographic factors, having a member of the household smoke 
inside the home and whether the respondents were bothered by second hand smoking.  
Analysis of national survey data of people living with MS found that having social support was 
beneficial for reducing pain. Having someone to take you to the doctor, confide/talk to, to do 
something enjoyable with and to take you to the emergency was found to be significantly 
associated with a lower reporting of pain.  In a separate analysis, using complementary treatment 
for MS was associated with lower odds of medication use. The use of behavior modification 
models as a tool for medication adherence is important for individuals living with chronic 
conditions who have a hard time coping with change.     
In an analysis of the effect of complementary therapies on MS, aerobic exercise such as treadmill 
training, cycling, aquatic exercise and high intensity interval training and physiotherapy was 
found to have greater effect on physical, mental and social health as opposed to other types of 
complementary treatments. 
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CHAPTER 1: AN INTRODUCTION TO MULTIPLE SCLEROSIS 
 
1.1 Demographic Factors Associated with Multiple Sclerosis 
 
Multiple sclerosis (MS) is a neurological disease of the central nervous system that attacks the 
myelinated axons.1–3 As of 2008, the countries with the highest estimated prevalence include 
Hungary (176 per 100 000), Slovenia (150), Germany (149), United States of America (135), 
Canada (132.5), Czech Republic (130),  Norway (125), Denmark (122), Poland (120) and Cyprus 
(110).4  The Canadian Institute for Health Information (CIHI) states that there are an estimated 
93,500 Canadians who live with MS which makes Canada one of the countries with the highest 
rates of this disease.5 In a recent study in Ontario, Canada found that the prevalence of MS 
increased by 69% from 1.57 per 1,000 in 1996 to 2.65 in 2013.6 This increase in prevalence was 
due to decline in mortality rates, the incidence remained stable.6  In another study based in 
Canada estimated the number of incidence MS cases per year to rise from 4051 cases in 2011 to 
4794 cases per 100 000 in 2031.7  
 
When looking at the demographic variables, women are affected in greater numbers in 
comparison to men and people of Northern European descent are at an increased risk.1 MS 
affects individuals starting between the ages of 20 to 45 years of age and though sometimes the 
disease starts in childhood.8–10 Both biological and environmental factors are associated with the 
disease.8–10 Life expectancy of patients with MS is shortened 7 to 14 years compared to the 
general population.11 However, disability as a result of the disease is progressive and therefore 
diminishes the quality of life over time.12 About 20% of patients are bedridden after 15 years 
following the onset of MS. Another 20% of patients may require a wheelchair or use crutches 
because of walking diffculties.12   
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1.2 Types of Multiple Sclerosis 
 
There are four categories of MS which include relapsing-remitting, secondary progressive, 
primary progressive and progressive relapsing MS.1 Approximately 85% of patients with MS 
have the relapsing remitting form which consists of episodic relapses and remissions. The first 
attack is known as a clinically isolated syndrome (CIS) which is a single episode of neurological 
symptoms which suggest that MS is present (figure 1.1).13  Magnetic resonance imaging (MRI) 
tests are usually done in order to find if there are any abnormalities in the brain or spinal cord.13 
If multiple attacks occur then the disease is seen as entering in the relapsing remitting stage 
(RRMS) (figure 1.2).13 RRMS is characterized by unpredictable relapses which are defined as 
flare-ups in which new symptoms may occur.13 After RRMS, the patients disease tend to evolve 
into secondary progressive MS (SPMS) (figure 1.3).13 In this stage relapses and remission 
become less noticeable and disease progression is steady.13  Only 15% of patients will have a 
primary progressive MS type and some will transition to progressive relapsing MS  (figure 
1.4).13 Progressive relapsing MS is caused by a slow progression in disability without relapses.13  
 
Figure 1.1: Clinically isolated syndrome is the first attack of MS on an individual and lasts for 24 
hours which causes inflammation or demyelination. Figure adapted from (MS Society of 
Canada,2018).13 
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Figure 1.2: Relapsing-remitting MS is the most common type with new symptoms 
appearing during relapses. Figure adapted from (MS Society of Canada,2018).13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Secondary progressive MS starts off with relapses and disability gets worse 
over time. Figure adapted from (MS Society of Canada,2018).13  
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Figure 1.4: Primary progressive MS is defined by a gradual increase in disability without 
relapses. Figure adapted from (MS Society of Canada,2018). 13   
 
1.3 Diagnosis of Multiple Sclerosis 
 
The diagnosis of MS is commonly based on the McDonald criteria which looks at the clinical 
presentation of symptoms.14 Based on the criteria, the number of attacks and number of lesions 
that are present are used to indicated whether an individual has MS.14 Magnetic resonance 
imaging (MRI) and cerebrospinal fluid (CSF) are used in order to make the diagnosis.14  
 
1.4 Genetic and Environmental Factors Associated with Multiple Sclerosis 
 
There are two prominent features of MS; 1) the disease occurs in clusters among families, and 2) 
the disease varies in frequency globally.15 In several twin studies, it has been suggested that the 
clustering in families is determined mainly by genetic factors however the regional difference in 
the prevalence of MS occurs from both genetic and population level environmental factors.16,17  
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The risk of developing MS is based on the degree of relatedness. Studies have shown that first, 
second and third degree relatives of people who have MS were also more likely to have the 
disease in comparison to the general population.18 Table 1-1 describes the risk factors for MS 
throughout the life course. The human leukocyte antigen (HLA) has been known to have the 
largest genetic contribution to MS susceptibility. In the early stages of life there are protective 
factors such as having protective human leukocyte antigen (HLA) haplotypes during in utero or 
childhood.19 Human leukocyte antigens are a cluster of genes on the short arm of chromosome 6 
and certain haplotypes such as HLA-DR1 and HLA-DR53 are considered to be protective 
against MS.20,21 During adolescence, protective factors include being exposed to the sun, having 
enough vitamin D levels and having a diet rich in fish oils. Although individuals can act on some 
protective factors, risk factors such as genetic predisposition to MS and sex of birth cannot be 
individually controlled.  
 
Table 1.1: Protective and risk factors associated with MS. Adapted from (Ramagopalan et al., 
2010).22  
 
Stages of life Protective factors Risk Factors 
In utero  Protective HLA haplotypes  Family history or genetic factors 
 Female sex 
 Being born in May 
 Born in high latitude regions 
 
 
Childhood 
 
 
Adolescence 
 Amount of sun exposure 
 Vitamin D supplements 
 Diets high in fish oils 
 Exposure to Epstein Barr virus 
 Smoking 
 Vitamin D deficiency 
 Living in high altitude regions 
 
Adulthood  
 None identified   Exposure to Epstein Barr virus 
 Smoking  
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Along with genetics, environmental factors have been known to play a role in MS 
development.9,23 Epstein-Barr virus (EBV) has been found to be a risk factor in many studies.9  
The risk for MS increases among individuals who have a history of infectious mononucleosis 
which occurs due to EBV infection as a teenager or in adulthood.9 The increased risk of 
developing MS for individuals who had EBV is possibly due to the enhanced permeability of the 
blood brain barrier which is triggered by the acute primary EBV infection.24 Once the B-cells 
cross the blood brain barrier and enter CNS, various mechanisms take part that result in the 
development of MS pathology.24 Other environmental factors such as smoking and lack of 
vitamin D can result in an interaction with EBV which could also lead to MS.24 However, some 
studies have found that there is a low risk for MS among individuals who are seronegative for 
EBV and more than 95% of the adult population are infected with EBV therefore it is not 
possible for all of them to develop MS.9 This is known as the EBV paradox.  
 
Other risk factors for MS include cigarette smoking. Studies have indicated that smoking 
increases the risk of conversion from clinical isolated syndrome to MS.22,25 Several studies have 
found an increased risk of developing MS among individuals who smoke cigarettes.26 One study 
found a hazard ratio of 3.6 (95% CI 1.3 to 9.9) for individuals who had ever smoked a cigarette 
compared with individuals who had never smoked.26 Another study done in Sweden found that 
smoking affects the risk of developing MS regardless of the age at exposure and both duration 
and intensity of smoking increases the risk of MS.27  Second hand smoke exposure is associated 
with many health effects such a cardiovascular disease and cancer and is also a risk factors for 
MS. In a study done on passive smoke exposure and its effect on MS, it was found that exposure 
to smoke is associated with higher risk of developing MS.28  
 
Lack of vitamin D is also a risk factor for MS. Vitamin D is available from two sources, the first 
is through exposure to ultraviolet B radiation (UVB) through sunlight and the second is through 
diet.29  Foods such as milk, cereal, orange juice, cheese, salmon, tuna and vitamin supplements 
contains vitamin D2.29  Increased vitamin D which is associated with lower risk of MS could be 
due to apoptosis of the autoreactive B-cells.24 There is an inverse relationship between amount of 
UVB received from sunlight and vitamin D concentration. One study found that individuals who 
were exposed to sunlight for at least 2 hours per day had lower odds of getting MS OR=0.47  
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(95%CI 0.26 to 0.84).29  Another study found that higher sun exposure as a child and in early 
adolescence was associated with a decreased risk of MS development.30 
 
 However, other studies have found that vitamin d levels and sunlight are independent of each 
other.31 Vitamin D supplementation compared to natural sunlight has still not been proven to be 
effective in altering disease activity.31 Regardless of whether these hypothesis are valid,  
individuals who have low levels of vitamin D could still take these supplements at moderate 
doses as a protective mechanism.31  
 
 
1.5 Treatment for Multiple Sclerosis 
 
There is no cure for the disease, however, there are several treatment options for minimizing the 
symptoms of MS such as medication, venous angioplasty, stem cell therapy, urinary 
catheterization, rehabilitation and psychotherapy however, medication is the most widely used 
treatment for controlling symptoms of MS and preventing relapses from occurring.32 Disease 
modifying therapies help shorten the duration of MS attacks and decrease their frequency. There 
are currently eight types of medications that are used to reduce disease progressions.1 These 
include drugs such as Beta interferons (Avonex, Rebif, Betaseron, Extavia), Glatiramer acetate 
(Copaxone), Mitroxantrone (Novantrone), Natalizumab (Tysabri), Fingolimod (Gilenya).1 Since 
medications don’t cure MS, many patients turn to other types of treatments and become less 
adherent to taking medication as prescribed. One of the most controversial treatments is an 
angioplasty procedure known as liberation therapy in which the “blocked” veins are opened up in 
order to improve blood flow and drainage from the brain.33 Chronic cerebrospinal venous 
insufficiency (CCSVI) in which the veins are blocked was proposed by the Italian physician Dr. 
Zamboni as the cause of MS, however evidence now strongly suggests that CCSVI does not lead 
to MS.34–36   
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1.6 Complementary treatment for MS 
 
 
Complementary treatment is treatment that is used along with medication.37 Non-invasive MS 
treatments include a wide range of options such as exercise, food and diet, stress management 
and acupuncture.37 At least a third of MS patients have used complementary and alternative 
treatments (CAM). Exercise is one type of complementary treatment that has been shown to 
improve movement and balance among patients with MS. In addition, exercise reduces stress and 
promotes recovery in patients with MS.38,39 However there has been few studies that have 
examined the effect of various types of exercises and physical therapy on the different domains 
of quality of life such as physical, mental and social. Although exercise may benefit overall 
quality of life, the effects on specific domains such as the physical domain; the mental and social 
domains has been less studied.  
  
Types of complementary treatment include cannabis, diet, exercise, vitamin and mineral 
supplements, relation techniques, acupuncture, massage and psychological approaches.40 Many 
reviews have stated that exercise and yoga has improved many aspects of a person’s life 
especially in those with MS.41  Yoga is an Indian practice that incorporates mind and body 
awareness. There are many types of yoga such as Hatha which focuses on poses and breathing, 
Ashtanga and Vinyasa yoga which is more physically demanding, Iyengar yoga which is based 
on the precision of the poses, Bikram yoga which is taught in a heated room and Kundalini yoga 
based on breathing and physical poses.42 In a randomized controlled trail of yoga and exercise in 
MS it was found that subjects with MS who participated in either a 6 month yoga or exercise 
class showed an improvement in fatigue as opposed to the control group.43 In another study done 
on an Ananda yoga program found that significant improvements were found in strength, 
balance, mental health and overall quality of life.44  Other types of complementary treatments 
such as massage therapy has also been found to reduce pain, improve balance and walking speed 
and those who used both massage therapy and exercise therapy were also found to reduce pain.45   
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1.7 The health care cost of MS 
 
In Canada the total per capita health care cost for adults who were 20 and older in 2011 was 
$16,800 for individuals with MS.7 The total annual heath sector costs for MS is expected to risk 
to $2 billion by 2013.7 In a study done in Canada where MS patients completed a web based 
questionnaire, it was found that the mean cost per patient per year increased as disability 
increased.46 Patients with mild disability define by an expanded disability status scale (EDSS) 
score from 0 to 3 spent a mean of $30,836 per year and for a patient with severe disability (EDSS 
4 to 6.5) a patient spent a mean of $77,981 per year.46 Another Canadian study stated that the 
largest cost associated with EDSS was the inability to work which increased as EDSS 
increased.47 However if disease progression is delayed or slowed these costs can be reduced.  
 
 
1.8 Overview of MS in Canada 
 
Canada has one of the highest rates of MS in the world.48 Based on the Survey of Living with 
Neurological Conditions in Canada (SLNCC) 2010 to 2011 there were 93,500 Canadians 
diagnosed with Multiple Sclerosis (MS) with a prevalence of 290 cases per 100,000 people.49  
The crude prevalence rate was steady from 2003 to 2012 for males and females. The crude 
prevalence was in the range of 2 to 3 per 1,000 for females and for males the prevalence was 
around 1 per 1,000 (Figure 1.5).   
 
The age standardized incidence rates per 100,000 for individuals 20 years of age and older are 
shown below in Figure 1.6. Throughout the years the age standardized incidence rates were 
greater in females as opposed to males with a rate of approximately 20 to 30 per 100,000.50 
These rates were steady from 2003 to 2012. However for males the rates were approximately 10 
per 100,000 from 2003 to 2012.50 The crude incidence rates of MS varied between age groups 
and sex; see figure 1.7. Individuals between the ages of 35 to 49 had the highest crude incidence 
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rate of MS per 100,000 people in 2015.50 A study done on timing of birth and risk of multiple 
sclerosis found that in Canada fewer patients with MS were born in November compared with 
controls.51  This was confirmed in a British dataset where there were more people with MS who 
were born in May.51 One of the explanations for this association is that the seasons may affect 
with the development of the central nervous system and immune system. Maternal level of 
vitamin D could be correlated to increased births of MS in certain months of the years.51  
 
Regional variation of MS prevalence in Canada was also identified (Table 1.2).48 One study has 
pointed out that the areas of the major cities in the prairies being located further north than in the 
other regions could be a possible explanation for the increased prevalence.48  
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Figure 1.5: Multiple sclerosis crude prevalence rate for individuals aged 20 years and older in Canada from 2003 to 2015. 
Adapted from (Public Health Agency of Canada, Public Health Infobase, 2018).50 
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Figure 1.6: Multiple sclerosis age standardized incidence rate per 100,000 for individuals ages 20 years and older in Canada 
from 2003 to 2015. Adapted from (Public Health  
Agency of Canada, Public Health Infobase, 2018). 50 
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Figure 1.7: Multiple sclerosis crude incidence rate per 100,000 in Canada for 2015. Adapted from (Public Health Agency of Canada, 
Public Health Infobase, 2018). 5
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Table 1.2: Prevalence of MS in Canadian Provinces. Adapted from (Beck et al.,2005).48 
Regions in Canada Prevalence 
British Columbia 240 per 100,000 
Prairies (Alberta, Saskatchewan, 
Manitoba) 
340 per 100,000 
Ontario 230 per 100,000 
Quebec  180 per 100,000 
Atlantic Canada (New 
Brunswick, Newfoundland and 
Labrador, Nova Scotia, Prince 
Edward Island) 
350 per 100,00 
 
Based on the survey of living with neurological conditions in Canada (SLNCC), living with MS 
had a moderate, quite a bit or extreme effect on 63% of people’s lives.49 In addition to this, MS 
prevented sleep for the majority of MS patients (62%).49 In terms of social impact, more than 
half of survey respondents stated that MS had limited their job opportunity moderately or 
extremely.49 When looking at comorbidities associated with MS, bowel and or bladder problem 
seemed to be the major problem with 59% of people reporting they had this in comparison to the 
general population.  The next major problem were mood disorders with 22% of people reporting 
this problem followed by high blood pressure at 17% , heart disease at 5% and diabetes at 6%.49  
Psychiatric comorbidities such as depression and anxiety are common in MS and have been 
reported in many studies.52–54 Some ways to treat depression are through medication, cognitive 
behavioral therapy, exercise and electrical therapies.53 Studies have also investigated the impact 
of physical comorbidity on the health related quality of life (HRQoL) of people living with MS.55 
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It was found that increased disability, depression and anxiety symptoms, fatigue and physical 
comorbidity were associated with decreased HRQol.55  
In terms of treatment for MS, 82.5% stated they received treatment while 17.5% didn’t. The 
majority of patients (83.7%) received medications such as injections, infusions and pills. 48.5% 
of patients stated they used rehabilitation therapy, 27% used counselling or psychotherapy 
services, 25.3% used complementary or alternative medications, 15.6% used urinary 
catheterization and 10.3% used venous angioplasty/liberation therapy procedures.49 
 Managing MS involves many health care providers along with tests which are costly. In a cross 
sectional analysis of 669 adults with MS who were enrolled in a province wide observational 
study between 2011 and 2013 found that over the two years of follow-up, there were 150 
hospitalizations which involved 99 patients and 11,213 outpatients visits which involved 637 
patients.56 In addition to this, individuals with MS are living a long period of time with the 
illness which reduces the quality of life. Based on the study done on MS mortality rates in 
Canada from 1975-2009, it was found that the highest mortality rates were after 2000 (Figure 1-
6).57 In 2013, the total number of deaths were 252,338 in Canada of which 521 deaths were due 
to MS.49  
 
A study on the relative mortality and survival in MS based on British Columbia MS registry 
from 1980 to 2007 found that the median survival age was 78.6 years for women and 74.3 for 
men.58 The survival was long for relapsing onset (R-MS) with an age of 49.7 years than for 
primary progressive MS (PPMS) which had a survival age of 32.5 years.58 The reduced survival 
time for people with PPMS could be due to the delays that occur for diagnosis.59 The MS 
survival times were considered long for this study, however in comparison to the general 
population the risk of death was still considered greater.58  
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Figure 1.8: Mortality rates from MS in Canada from 1975 to 2009. Adapted from (Public Health Agency of Canada, Public 
Health Infobase, 2018).57
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CHAPTER 2: OBJECTIVES OF THIS RESEARCH 
 
2.1 Rationale for this Research 
 
The purpose of this research is to explore at a population level the gaps in MS research in terms of 
prevention of risk factors such as second hand smoking and to explore factors associated with 
medication use and exercise uptake. In addition, this research explores the psychosocial factors 
associated with MS and how these factors contribute to the pain experienced by MS patients. 
Although there has been extensive MS research exploring the risk factors of the disease, not much 
of the research has examined the issues at a population level.  
 
2.2 Context of this Research 
 
This research examines areas of MS from risk factors, through symptoms to treatment options 
and their impact on patients’ well-being. The four areas of research concern: 1) the general 
population’s knowledge about a specific risk factor for MS (second hand smoking), 2) predictors 
of pain in MS patients, 3) factors associated with medication adherence for MS, and 4) types of 
complementary treatment for MS and their effect on the health and well-being of MS patients. 
This research will help improve our knowledge of MS and its treatment. Hopefully the findings 
will inform policies and programs that are created to provide better patient care.   
 
Chapter 2 gives an overview of multiple sclerosis in Canada in terms of rates of MS throughout 
the years, rates of MS based on provinces and common comorbidities associated with MS.  
 
Chapter 3 investigates Canadian data on the predictors associated with people’s level of 
agreement on whether second hand smoking is a risk factor for MS. The data on smoking was 
obtained from the Health Canada: Smoking Survey (2004-2005). The analysis also examined 
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whether their perception of whether second hand smoke exposure could lead to MS development 
varies depending on the province in which they live, smoking levels in those provinces and other 
characteristics of their immediate social environment. A multilevel mixed effects logistic 
regression model will be created and odds ratios will be calculated to assess whether individual 
level and area level factors are associated with odds of people agreeing to second hand smoke 
exposure leading to development of MS.  
 
Chapter 4 explores aspects of pain, a very common symptom of MS. The main question 
examined is, “does a lack of support from family or friends have an interaction effect on a lack 
of sleep and mental health problems and further whether this is associated with reported pain 
among individuals with MS?” The data examined is from the national Canadian Survey of 
Living with Neurological Conditions.  Multivariate logistic regression is used.  
 
The next two chapters explore aspects of the treatments for MS. Chapter 5 examines the 
predictors of medication use in people living with MS. Data from the national Survey of Living 
with Neurological Conditions in Canada (SLNCC) is again used and a multivariate logistic 
regression analysis was conducted.  
 
Chapter 6 is a meta-analysis of a variety of complementary treatment modalities such as exercise 
types, yoga and physical therapy on their impact on the physical, mental and social health of 
people living with MS. The final chapter summarizes our findings and discusses potential 
avenues for further research and the policies and programs to provide better treatment for MS 
patients. 
 
2.3 Study Design 
This thesis uses two general types of study designs. Cross sectional survey designs are used in 
chapters 3, 4 and 5 and a systematic review with meta-analysis is used in chapter 6. Cross 
sectional studies are more advantageous over other study designs because it is relatively 
inexpensive, many outcomes and risk factors can be assessed and it takes less time to carry out.1 
The disadvantage is that measurement occurs only at one point in time therefore causality cannot 
be inferred.  
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Meta-analysis combines the results of multiple studies which allows results to be generalized to a 
larger population.2 However the disadvantages of this is that several small studies cannot 
replicate the result of a single large study and a meta-analysis cannot correct for biases which 
may have occurred in the original studies.2  
 
2.4 Data Sources 
The data examined in Chapters 3, 4, 5 are from large scale national Canadian surveys. In Chapter  
3 the analysis is from the 2005 Health Canada-Smoking survey. The survey conducted by Health 
Canada collected information about the Canadian general public which included smokers and 
non-smokers in the provinces of Quebec, Ontario, Saskatchewan, Newfoundland and British 
Columbia. The final sample consisted of 1,404 people in Quebec, 1,443 people in Ontario, 1,413 
people in Saskatchewan, 1,442 people in Newfoundland and 1,468 people in British Columbia.3,4 
The surveys measured knowledge attitudes and behaviours of the population of both smokers 
and non-smokers in each of the provinces. 
The Survey of Living with Neurological Conditions in Canada (2011) was used for the analysis 
in chapters 4 & 5.5 This survey is a cross sectional survey that was linked to the Canadian 
Community Health Survey (CCHS).6 The CCHS collects information which is related to the 
health status, health care utilization and health determinants for the Canadian population. For 2 
years (2010 and 2011), the CCHS collected information on a set of 18 neurological conditions 
and participants who had one of these conditions were recruited to participate in the SLNCC. 
The SLNCC sampled the population of household residents who were 15 years of age and older 
in one of Canada’s 10 provinces. The final sample consisted of 8,200 people with neurological 
conditions with a response rate of 81.6%.5  
   
For the meta-analysis in Chapter 6, articles from 1990 to 2017 (27 years) were collected from a 
database search from PubMed, Medline and Scopus using specific search strategies with detailed 
inclusion and exclusion criteria applied to screen the articles that are to be selected for inclusion 
in the systematic review and meta-analysis. 
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2.5 Statistical Analysis 
 
This thesis uses a variety of statistical analyses depending on the nature of the question being 
examined. Descriptive analysis is used to explore the demographic characteristics of the 
population and samples surveyed. Multilevel mixed effects logistic regression analysis (Chapter 
3) is used for binary outcomes as well as to explore the area level effect on the outcome. 
Multivariate logistic regression (Chapter 4 and 5) will be used for binary outcomes in order to 
determine odds ratios.  
For chapters  4 and 5 where SLNCC data sets were used, replicated sampling weights and 
bootstrapped variance estimation were used as recommended by Statistics Canada in order to 
take into account the survey design 5 A set of (n=500) replicate weights were used in order to 
account for non-responses. The bootstrapping sampling weights used in the analysis were created 
for SLNCC by Statistics Canada. For the SLNCC linked data set, the bootstrap replicates are the 
sub samples that were drawn and used to estimate the variance of the CCHS estimates.5 In order 
to take into account the SLNCC sample design, each of the CCHS bootstrap replicates were 
adjusted. 5 
For the meta-analysis (Chapter 6) Cohen’s d which is the mean difference is computed for 
physical health scores, mental health scores and social health scores.7 The standard mean 
difference will be calculated based on the mean difference between the treatment and control 
group divided by the pooled standard deviation.7 
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CHAPTER 3: PREDICTORS OF PEOPLE’S PERCEPTIONS OF SECOND HAND 
SMOKE EXPOSURE AS A RISK FACTOR FOR MULTIPLE SCLEROSIS 
 
Abstract 
 
Objective: There are many health problems associated with exposure to second hand smoke 
exposure. Being exposed to second hand smoking earlier in childhood may cause development of 
MS. The primary objective of this study was to examine the predictors associated with people’s 
perception on second hand smoke exposure being a risk factor for MS.   
 
Methods: The data set was drawn from the Health Canada: Smoking Survey conducted in 2004 
and 2005 by Environics Research Group in partnership with Health Canada to survey the public 
in the province of British Columbia (N=1,468), Newfoundland (N=1,442), Quebec (N=1,404), 
Ontario (N=1,443) and Saskatchewan (N=1,413). A multilevel mixed effects logistic regression 
model analysis was carried out in order to determine whether people’s perceptions of second 
hand smoking as a risk factor for MS varied based on the province of residence. 
 
Results: Age, sex, having a household member who smoked inside their home, if respondents 
were bothered by second hand smoke exposure and smoking status were associated with 
increased odds of people agreeing to second hand smoke exposure being a risk factor for MS 
development. In addition to this the province of residence was associated with survey 
respondents agreeing or disagreeing to whether second hand smoke exposure is associated with 
MS development. 
Conclusion: The study results could guide in the development of stop second hand smoking 
campaigns on social media, TV and bus stop shelters. This could help raise awareness about the 
risk of second hand smoking and its association on the risk of development of MS.
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3.1 Introduction 
 
Second hand smoke exposure is detrimental to health since it leads to ischaemic heart disease, 
lower respiratory infections, asthma and lung cancer.1 There are many environmental factors that 
are associated with multiple sclerosis (MS) development and exposure to cigarette smoke is one 
of them.2 However people’s perceptions about second hand smoke exposure on MS development 
is an understudied area.  
 
Recent studies have reported the harmful effects of second hand smoke exposure on 
development of MS among children as well as adults.3–5 Children who had parents who smoked 
were a greater risk of having a first episode of MS RR=2.12 (95% CI 1.43 to 3.15).5 Hedstrom et 
al. 2011 assessed the effect of passive smoking on the risk of MS and found that  individuals 
who have never smoked were at a 1.3 times greater odds  95% CI (1.1-1.6) of developing MS if 
they were exposed to passive smoking.3 Passive smoking as a risk factor for MS is a fairly new 
topic that hasn’t received much attention. Therefore not many people are aware of the impact 
that second smoke exposure has on MS. Many smoking campaigns inform people about smoking 
and risk of lung cancer and cardiovascular disease but fail to talk about its impact on MS 
development.   
 
In a meta-analysis study conducted by Zhang et al.2016 on risk of smoking on MS, they found 
that along with smoking being a risk factor for MS development, passive smoke exposure also 
increased the risk of developing MS as opposed to individuals who were unexposed.6 Some 
studies have stated that that a person’s genetic background also plays a role in whether passive 
smoke exposure will result in MS development later on in life. Individuals who have a special 
class II allele HLA-DRB1*15 were 3 times more likely to develop MS as opposed to individuals 
who don’t have the allele.7–9  
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Hedström et al. (2014) explored the interaction of passive smoking and HLA genotype and found 
that compared to non-smokers who did not have the two genetic risk factors (HLA-DRB1*15 
and HLA-A*02) individuals who had the two risk factors and who were not exposed to passive 
smoking were OR=4.5 (95% CI 3.3 to 6.1) times more likely to develop MS.10  However 
individuals who had the two genetic risk factors and who were exposed to passive smoking were 
OR=7.7 (95% CI 5.5 to 10.8) times more likely to develop MS.10 Thus indicating that 
development of MS is associated with genetic factors and could be influenced by exposure to 
passive smoking.10 Apparent in these studies is that both environment and genetics plays a role in 
MS development. 
 
MS is a rare condition, not many people will be aware of the condition or the risk factors 
associated with MS such as passive smoking. If people are not aware of the risk factor then 
prevention is difficult.  Several studies have been conducted on demographic factors of people’s 
perception of second hand smoke exposure in relation to lung cancer or chronic obstructive 
pulmonary disease. However studies on exploring people’s perception of second hand smoke 
exposure on MS is rare. It is important to evaluate population knowledge on MS so as to gain a 
better understanding on ways to educate people. The objective of this research is to determine the 
demographic, socioeconomic and personal predictors associated with people’s perception on 
whether they think that second hand smoking is a risk factor for MS. As a secondary objective, 
whether this perception varies based on the province of residence will also be examined in order 
to find out if there is a macro level effect. The model for this objective is shown in Figure 3.1.   
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Figure 3. 1: Model for predictors associated with people’s perceptions of whether second hand 
smoke exposure is associated with MS.  
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3.2 Methods 
 
3.2.1 Data Source 
The data set was drawn from the Health Canada: Smoking Survey conducted in 2004 and 2005 
by Environics Research Group in partnership with Health Canada to survey the public in the 
province of British Columbia (N=1,468), Newfoundland (N=1,442), Quebec (N=1,404), Ontario  
(N=1,443) and Saskatchewan (N=1,413) on smoking.11,12 This data file is a public use file. 
Random digit dial sampling process was used to select people in each province. The survey was 
conducted to measures the knowledge, attitudes and behaviors of the population towards 
smoking and second hand smoking in public places. Only individuals who were 18 years of age 
and older were included in the analysis.  
 
3.2.2 Study Sample 
There was a total of 7,170 respondents in the initial Health Canada Smoking survey. The study 
sample was restricted to individuals 18 years of age and older since this is the legal age of 
smoking. After age restriction was applied, there were 7,166 people respondents who remained. 
The sample was restricted to individuals who answered the question to whether second hand 
smoke can cause MS (N=4,815).  After missing values were removed, 4,229 observations 
remained for the analysis. Figure 3.2 shows the flowchart of study sample. 
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Figure 3. 2: Flow chart of study sample used for complete case analysis.  
British Columbia 
N=1,468 
Newfoundland 
N=1,442
Quebec
N=1,404
Ontario
N=1,443 
Saskatchewan
N=1,413
Total number of people 
in the Health Canada 
Smoking Canada 
N=,7170
Total number of people 
who remained in sample
N=7,166
Number of observations 
remained for the study
N=4,815
Final number of 
observations used in the 
analysis
N=4,229
Removed individuals 
before the age of 18
N=4
Sample restriction
Removed individuals who did 
not respond to the question 
“Second hand smoke can cause 
Multiple Sclerosis” (outcome) 
N=2,351
Missing values removed 
from variables 
N=586
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3.2.3 Variables assessed 
Survey respondents were asked whether they agree that second hand smoking was a risk factor 
for MS. Individuals were asked to rate their agreement and had 4 categories to choose from 
(strongly agree, somewhat agree, somewhat disagree or strongly disagree). In this analysis 
individuals who replied strongly agree or somewhat agree were classified as “1=Yes” and those 
who replied as somewhat disagree or strongly disagree were categorized “0=No”. This was the 
dependent variable of interest.  
The factors that were included in the analysis were sex, age, marital status, education, number of 
people living in the household, whether other members of the household smoked in the house, if 
they were bothered by second hand smoke, if they had children under the age of 18, the 
frequency of breathing in second hand smoke and smoking restrictions in either workplace, 
restaurant or shopping malls. The predictors used for the analysis are shown in Table 3.1.  
 
3.3 Analysis 
A two level multilevel mixed effects logistic regression model analysis was carried out in order 
to determine whether people’s perceptions of second hand smoking as a risk factor for MS varied 
based on the province of residence. Two approaches were used to build the final models and then 
compared to see which procedure gave better results. A complete case analysis was conducted in 
which only variables with complete values were used in the model and missing values were 
removed. Unadjusted and adjusted odds ratios with 95% CIs with p-values were computed. 
Univariate analysis was conducted using a (p <0.20). Manual backward selection was used to 
build the multivariable model based on (p<0.05). Confounders were tested in the final model and 
were retained if the addition of that variable changed the coefficients of the other variables by 
more than 20%.  Interactions were assessed and added to the model if they were significant at 
(p<0.05). Akaike’s information criterion (AIC) was used to compare fit of models. The 
effectiveness of the final model was assessed using receiver-operating characteristics (ROC) and 
plots of standardized residuals. The analysis was performed using STATA IC 15.13 
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As a secondary analysis, imputation was carried out in order to take into account bias, loss of 
power and precision that could be associated with missing values. The pattern of missingness 
was assessed. Based on the pattern of missingness for each variable, multiple imputation by 
chained equation was chosen. The method by Rubin et al. 1987 was used for the imputation 
procedure.14 Univariate analysis was conducted using a (p <0.20). Manual backward selection 
was used to build the multivariable model based on (p<0.05). Confounders and interaction terms 
were tested in the models and results were reported as ORs with 95% confidence intervals. 
Akaike’s information criterion (AIC) was used to compare fit of models. The effectiveness of the 
final model was assessed using receiver-operating characteristics (ROC). Both models based on 
complete case analysis and imputation were compared to find the best model for the data.  
 
3.4 Results 
 
3.4.1 Results based on complete case analysis  
The final sample consisted of 4,229 observations. Based on the descriptive statistics, there were 
1,639 individuals who agreed that second hand smoking causes multiple sclerosis (MS) and 
2,590 individuals who disagreed to second hand smoking causing MS. Figure 3-3 shows the 
number of respondents based on province of residence. Ontario and Saskatchewan had higher 
levels of responses. In terms of smoking status 60% were smokers and 40% were nonsmokers.  
When comparing across provinces, Newfoundland had the highest rate of people agreeing (49%) 
to second hand smoke exposure causing MS, while Quebec had the lowest percentage of people 
agreeing (33%) (Figure 3-4). Univariate analysis indicated that all predictors were significant 
with the dependent variable which are shown in Table 3-1. Based on the multivariate analysis 
sex, age, education, if members of household smoked inside home, if respondent was bothered 
by second hand smoke, their smoking status and the interaction between sex and smoking status 
was significant.  
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Figure 3. 3: Number of respondents by province. 
 
Figure 3.4:The percentage of respondents who agreed or disagreed to second hand smoke 
exposure being a risk factor for MS development out of 4,229 observations.
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Table 3. 1:Descriptive statistics and univariate analysis for perception of second hand smoking as a risk factor for MS based on 
complete case analysis (N=4,229). 
Variables OR 95% CI P-value  N      
Sex 
  
p<0.001* 
 
Male Ref 
  
2,074 
Female 0.78 0.69-0.88 p<0.001 2,155      
Age  
  
p<0.001* 
 
≤24 Ref 
  
496 
25 to 30 0.73 0.56-0.95 0.021 444 
31 to 36 0.84 0.65-1.07 0.164 519 
37 to 42 0.68 0.54-0.87 0.003 571 
43 to 48 0.58 0.45-0.74 p<0.001 576 
49 to 54 0.56 0.43-0.72 p<0.001 544 
55 to 60 0.55 0.42-0.72 p<0.001 469 
≥61 0.95 0.75-1.21 0.696 610      
Marital status  
 
0.0083* 
 
Married or living as a couple Ref 
  
2,566 
Single 1.03 0.88-1.20 0.69 1,028 
Widowed 1.2 0.90-1.60 0.213 207 
Separated 0.92 0.66-1.30 0.64 153 
Divorced 0.63 0.48-0.83 0.001 275      
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Variables OR 95% CI P-value  N 
 
Education  
 
p<0.001* 
 
Less than high school degree Ref 
  
727 
High school degree 0.63 0.51-0.77 p<0.001 915 
More than high school but less than 
university 
0.54 0.45-0.64 p<0.001 1,716 
University degree or greater 0.45 0.37-0.56 p<0.001 871      
Number of people living in household 0.0002* 
 
Less than 2 people Ref 
  
2,199 
Greater than 3 people 1.27 1.12-1.43 p<0.001 2,030      
Do other members of your household smoke inside your home? p<0.001* 
 
Yes 0.67 0.58-0.78 p<0.001 1,076 
No Ref 
  
3,153      
Bothered by second hand smoke                                                                                                                        
p<0.001* 
 
Very much Ref 
  
1,263 
Somewhat 0.56 0.47-0.66 p<0.001 1,151 
Not very much/not at all 0.31 0.27-0.36 p<0.001 1,815      
Smoking status 
 
p<0.001* 
 
Smoker Ref 
  
2,551 
Non-smoker  1.95 1.72-2.21 p<0.001 1,678 
 
 
 
    
  
 
 
4
0
 
   
     
          
Variables OR 95% CI P-value  N 
Children in household under age of 18 0.0043*    
Yes 1.21 1.06-1.37 0.004 1,552 
No Ref   2,677 
     
Frequency of breathing in second hand smoke p<0.001*  
Everyday Ref 
  
1,849 
Once to few times a week 1.43 1.23-1.66 p<0.001 1,225 
Less than a month to 3 times a month 1.27 1.08-1.49 0.004 979 
Never 1.42 1.03-1.95 0.028 176      
Smoking restriction in workplace or restaurant or shopping malls p<0.001* 
 
Yes 0.7 0.59-0.82 p<0.001 3,497 
No  Ref 
  
732 
* Significance at p<0.20  
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Table 3. 2: Multivariate analysis for perceptions of second hand smoke as a risk factor for MS based on complete case analysis 
(N=4,229). 
Variables OR 95% CI P-value N  
Sex 
 
 p<0.001* 
 
Male  1.67 1.40 -2.00 p<0.001 2,074 
Female  ref  
 
2,155   
 
  
Age  
 
 p<0.001*  
≤24 ref  
 
496 
25 to 30 0.83 0.62-1.10 0.193 444 
31 to 36 0.86 0.65-1.15 0.309 519 
37 to 42 0.67 0.50-0.89 0.006 571 
43 to 48 0.59 0.44-0.79 0.000 576 
49 to 54 0.57 0.42-0.77 0.000 544 
55 to 60 0.55 0.40-0.76 0.000 469 
≥61 0.86 0.63-1.19 0.365 610   
 
  
Marital status 
 
 0.54 
 
Married or living as a couple ref  
 
2,566 
Single 0.97 0.80-1.17 0.744 1,028 
Widowed 1.01 0.72-1.42 0.938 207 
Separated 1.01 0.71-1.45 0.948 153 
Divorced 0.77 0.57-1.04 0.085 275   
 
  
Education  
 
 p<0.001*  
Less than high school degree ref  
 
727 
High school degree 0.58 0.47-0.72 p<0.001 915 
Greater than high school diploma but 
less than university degree 
0.46 0.38-0.57 p<0.001 1,716 
University degree or greater 0.31 0.25-0.40 p<0.001 871   
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Variables OR 95% CI P-value N  
Number of people living in 
household including themselves 
 
 0.10 
 
Less than 2 people ref  
 
2,199 
Greater than 3 people 1.17 0.97-1.41 0.097  
     
Do other members of your household 
smoke inside your home? 
 
 0.03* 
 
Yes ref  
 
1,076 
No 1.22 1.02-1.45 0.029 3,153   
 
  
Bothered by second hand smoke   p<0.001  
Very much 3.27 2.69-3.97 p<0.001 1,263 
Somewhat 1.80 1.52-2.14 p<0.001 1,151 
Not very much/not at all ref  
 
1,815   
 
  
Smoking status  
 
 p<0.001* 
 
Smoker ref  
 
2,551 
Non smoker 1.50 1.20-1.87 0.000 1,678   
 
  
Children in household under age of 
18 
 
 0.45 
 
Yes 1.08 0.88-1.32 0.450 1,552 
No 
 
 
 
2,677   
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Variables OR 95% CI P-value N  
Frequency of breathing in second 
hand smoke 
 
 0.05 
 
Never  ref   176 
Everyday 0.91 0.64-1.30 0.604 1,849 
Once to few times a week 1.04 0.74-1.48 0.810 1,225 
Less than a month to 3 times a month 0.88 0.57-1.15 0.228 979 
     
Smoking restriction in workplace or 
restaurant or shopping malls 
 
 0.08 
 
Yes 0.85 0.71-1.02 0.077 3,497 
No  ref  
 
732   
 
  
Interaction of Sex and Smoking 
status 
 
 0.01* 
 
Male×smoker 1.42 1.09-1.87 0.010 
 
  
 
  
* Significance at p<0.05 
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In the model building process marriage status, number of people in the household, the frequency 
of breathing in second hand smoke and smoking restriction in either workplace, restaurant or 
shopping malls were removed (p-values>0.05). When testing for confounders it was found that 
all the variables removed were confounders and were included back into the model. The 
interaction of sex and smoking status was found to be significant at (p=0.01). Table 3-2 shows 
the multivariate analysis. Males (OR=1.18 95%CI 1.40 to 2.00) were more likely to agree that 
second hand smoke could cause MS compared to females. 
 
 A gradient effect was seen in age whereby as age increased the less likely people were to agree 
to second hand smoking causing MS.  Individuals between the ages of 37 to 42 years of age were 
less likely to agree to second hand smoking causing MS (OR= 0.67 95%CI 0.50 to 0.89) 
compared to individuals who were less than 24 years of age. Similar findings were found for 
individuals between the ages of 43 to 48 (OR=0.59 95%CI 0.44 to 0.79), 49 to 54 (OR=0.57 
95% CI 0.42 to 0.77) and 55 to 60 years of age (OR=0.55 95%CI 0.44 to 0.76). Table 3-3 shows 
comparison between age categories.  
 
When comparing between ages, individuals who were 61 and over were more likely to agree that 
second hand smoke causes MS in comparison to those who were 43 to 48 years of age (OR=1.46 
95% CI 1.10 to 1.94), 49 to 54 years (OR=1.52 95%CI 1.16 to 2.00) and 55 to 60 years of age 
(OR=1.57 95% CI 1.19 to 2.08). Education was significant in the final model whereby 
individuals with a high school degree (OR= 0.58 95% CI 0.47 to 0.72) were less likely to agree 
that second hand smoking could cause MS. Individuals with greater than high school diplomas 
but less than university degree (OR=0.46 95%CI 0.3 to 0.57) were less likely to agree to second 
hand smoke causing MS compared to individuals with less than a high school degree. Similar 
results were found for individuals with a university degree (OR=0.31 95%CI 0.25 to 0.40) or 
greater. However, the odds ratios remained within the same range across different levels of 
education levels with only slight differences.  
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Having household members who smoke inside their home was also associated with whether or 
not people think that second hand smoke could cause MS. Individuals who had no household 
members who smoked in their home were more (OR=1.22 95%CI 1.02 to 1.45) likely to agree 
that second hand smoke could cause MS. The level that people felt bothered by second hand 
smoking was also associated with whether or not they felt that second hand smoking could cause 
MS.  
 
Individuals who were very much bothered by second hand smoke were more (OR=3.27 95% CI 
2.69 to 3.97) likely to agree that second hand smoke could cause MS compared to those who 
were not very much bothered or who were bothered not at all. Similar results were found for 
individuals who were somewhat bothered by second hand smoke (OR= 1.80 95%CI 1.52 to 
2.14). Smoking status was also found to be significant in the model. Non-smokers were more 
(OR=1.50 95%CI 1.20 to 1.87) likely to agree that second hand smoke leads to MS compared to 
smokers. 
 The interaction of sex and smoking status was significant in the final model. Male smokers were 
more (OR=1.42 95%CI 1.09 to 1.87) likely to agree that second hand smoke causes MS. When 
comparing interaction terms, it was found that female non-smokers were more (OR=1.50 95%CI 
1.20 to 1.87) likely to agree that that second hand smoke causes MS compared to female 
smokers. Significance was also found when comparing female smokers to male smokers 
(OR=0.60 95% CI 0.50 to 0.71) as well as between female smokers and male non-smokers but to 
a lesser extent (OR= 0.57 95% CI 0.45 to 0.71).   
 
The interactions in the model are depicted in Figure 3-5. Non-smoking females had a higher 
probability of agreeing to second hand smoke exposure leading to MS development compared to 
female non-smokers. Male smokers had a higher probability of agreeing that second hand smoke 
exposure leads to MS development compared to female smokers. Figure 3-6 shows that as age 
increased the probability of agreement to second hand smoke exposure decreased. Figure 3-7 
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shows that those who were very much bothered by second hand smoking had a greater 
probability of agreement to the question as opposed to those who were not bothered by second 
hand smoke exposure. The ROC curve suggested that that the multilevel mixed effects logistic 
regression model correctly classified 70% of people on their perceptions of whether second hand 
smoke causes MS indicating a fair model (95% CI 0.69 to 0.72). The model without interaction 
term was compared to the model with an interaction term using Akaike’s information criterion 
(AIC). The results indicated that the model with the interaction term with sex and smoking status 
had an (AIC= 5,201) compared to the model without the interaction term (AIC= 5,205). 
Therefore the model with the interaction term was considered better since it has a lower AIC. For 
the random effects of the model, 1.9% of the total variability in the dependent variable was 
explained by the province level.  
Table 3. 3: Comparison of categorical variables that were significant from multivariate analysis 
based on p<0.05.  
  OR  95% CI 
Age Comparison   Lower Upper 
61 and over vs 43 to 48 1.46 1.10 1.94 
55 to 60 vs 49 to 54 0.97 0.73 1.28 
61 and over vs 49 to 54 1.52 1.16 2.00 
61 and over vs 55 to 60 1.57 1.19 2.08 
Interaction of Sex and Smoking Status     
Male     
(Male#non-smoker) vs (Male#smoker) 1.05 0.85 1.31 
(Female#smoker) vs (Male#smoker) 0.60 0.50 0.71 
(Female#non-smoker) vs (Male#smoker) 0.90 0.72 1.12 
(Female#smoker) vs (Male#non-smoker) 0.57 0.45 0.71 
(Female#non-smoker) vs (Male#non-smoker) 0.85 0.69 1.05 
(Female#non-smoker) vs (Female#smoker) 1.50 1.20 1.87 
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Figure 3. 5: Predicted probabilities and 95% CI of agreement for second hand smoking as a risk factor for MS by sex and smoking 
status.  
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Figure 3. 6: Predicted probabilities and 95% CI of agreement for second hand smoking as a risk factor for MS by age. 
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Figure 3.7:Predicted probabilities and 95% CI of agreement for second hand smoking as a risk factor for MS by whether respondent 
was bothered by second hand smoke exposure.  
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3.4.2 Results based on Multiple Imputation  
 
The results based on the multiple imputation procedure was similar to the results from the 
complete cases analysis output (table 3-4 and table 3-5). All of the variables which were 
screened in the univariate analysis were significant and were included in the multivariate 
analysis model building process. Table 3-4 shows the output for the univariate analysis based on 
multiple imputation procedures. In the model building process, number of people living in the 
household, marital status, whether members of the household smoked, whether there were 
children in the household younger than 18 years of age, the frequency of breathing in second 
hand smoke and smoking status were removed based on a p-value of 0.05, however all were 
included back into the model due to the variables being confounders. 
 
Based on the comparison between models, the model based on complete case analysis explained 
a larger portion of the total variance (1.9%) in people’s responses to the question on second hand 
smoke exposure than the model based on imputation procedures (1.3%).  Based on the results of 
the ROC analysis, the final model based on complete cases analysis correctly classified 70% of 
people on their perception of second hand smoke exposure, however the model based on the 
imputation procedures correctly classified 65% of people on their perceptions of second hand 
smoke exposure. The AIC was 7,832 for the multiple imputation model, which is larger 
compared to the model with complete case analysis AIC= 5,201. After comparison of the models 
and fit of the data, the model based on complete case analysis was better compared to the model 
based on the imputation procedures.  
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Table 3.4:Descriptive statistics and univariate analysis for perception of second hand smoking as 
a risk factor for MS based on multiple imputations (N=7,166).  
Variables OR 95% CI P-value  
 
   
Sex   p<0.001* 
Male Ref   
Female 0.75 0.69-0.88 p<0.001 
 
   
Age    p<0.001* 
≤24 Ref   
25 to 30 0.70 0.56-0.89 0.003 
31 to 36 0.70 0.57-0.88 0.002 
37 to 42 0.57 0.46-0.70 p<0.001 
43 to 48 0.47 0.38-0.58 p<0.001 
49 to 54 0.46 0.37-0.57 p<0.001 
55 to 60 0.46 0.36-0.57 p<0.001 
≥61 0.57 0.47-0.69 p<0.001  
   
Marital status    p<0.001* 
Married or living as a couple Ref   
Single 1.17 1.03-1.33 0.017 
Widowed 0.85 0.68-1.07 0.179 
Separated 0.96 0.71-1.29 0.777 
Divorced 0.62 0.49-0.79 p<0.001 
    
Education    p<0.001* 
Less than high school degree Ref   
High school degree 0.73 0.62-0.86 p<0.001 
More than high school but less than university 0.61 0.53-0.71 p<0.001 
University degree or greater 0.48 0.40-0.57 p<0.001 
 
   
Number of people living in household   p<0.001* 
Less than 2 people Ref   
Greater than 3 people  1.26 1.13-1.40 p<0.001 
    
Do other members of your household smoke inside your home?   0.054 
Yes 0.88 0.77-1.00 0.054 
No Ref   
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*Significance based on p<0.20  
 
 
 
 
 
 
 
 
Variable  OR 95% CI P-value  
Bothered by second hand smoke   p<0.001* 
Very much Ref   
Somewhat 0.72 0.63-0.83 p<0.001 
Not very much/not at all 0.51 0.45-0.56 p<0.001 
    
Smoking status   p<0.001* 
Smoker Ref   
Non-smoker  0.69 0.62-0.77 p<0.001 
    
Children in household under age of 18   0.004* 
Yes 1.17 1.05-1.31 0.004 
No Ref   
    
Frequency of breathing in second hand smoke   0.014* 
 
Everyday Ref   
Once to few times a week 1.20 1.06-1.37 0.005 
Less than a month to 3 times a month 0.98 0.85-1.12 0.718 
Never 1.04 0.81-1.33 0.778 
    
Smoking restriction in workplace or restaurant or shopping malls   p<0.001* 
Yes 0.70 0.58-0.78 p<0.001 
No  Ref   
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Table 3. 5:Multivariate analysis for perceptions of second hand smoke as a risk factor for MS 
based on multiple imputation. 
Variables OR 95% CI P-value 
Sex 
 
 p<0.001* 
Male  1.57      1.34-1.83 p<0.001 
Female  ref  
 
  
 
 
Age  
 
 p<0.001* 
≤24 ref   
25 to 30 0.80 0.63-1.03 0.08 
31 to 36 0.76 0.60-0.97 0.029 
37 to 42 0.60 0.47-0.76 p<0.001 
43 to 48 0.48 0.38-0.61 p<0.001 
49 to 54 0.47 0.37-0.61 p<0.001 
55 to 60 0.47 0.36-0.62 p<0.001 
≥61 0.53 0.41-0.69 p<0.001   
  
Marital status 
 
 0.30 
Married or living as a couple ref   
Single 1.00 0.86-1.17 0.98 
Widowed 0.89 0.69-1.16 0.39 
Separated 1.06 0.78-1.44 0.73 
Divorced 0.78 0.60-0.99 0.045   
  
Education  
 
 p<0.001* 
Less than high school degree ref   
High school degree 0.66 0.56-0.79 p<0.001 
Greater than high school diploma but less 
than university degree 
0.53 0.45-0.62 p<0.001 
University degree or greater 0.38 0.32-0.46 p<0.001   
  
Number of people living in household 
including themselves 
 
 0.28 
Less than 2 people ref   
Greater than 3 people 1.09 0.93-1.27 0.28 
    
Do other members of your household smoke 
inside your home? 
 
 0.81 
Yes ref   
No 1.02 0.8-1.18 0.81   
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Variable OR 95% CI P-value 
Bothered by second hand smoke   p<0.001* 
Very much 2.05 1.75-2.41 p<0.001 
Somewhat 1.46 1.26-1.69 p<0.001 
Not very much/not at all ref     
  
Smoking status  
 
 0.0003* 
Smoker ref   
Non smoker 1.40 1.16-1.67 p<0.001   
  
Children in household under age of 18 
 
 0.62 
Yes 1.04 0.88-1.32 0.62 
No ref     
  
Frequency of breathing in second hand 
smoke 
 
 0.061 
Never  ref   
Everyday 0.96 0.73-1.27 0.793 
Once to few times a week 1.07 0.82-1.40 0.619 
Less than a month to 3 times a month 0.87 0.67-1.14 0.312 
    
Smoking restriction in workplace or 
restaurant or shopping malls 
 
 0.0004* 
Yes 0.77 0.67-0.89 p<0.001 
No  ref     
  
Interaction of Sex and Smoking status 
 
 0.037* 
Male×smoker 0.79 0.63-0.94 0.037   
  
*Significance at p<0.05 
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3.5 Discussion  
The main objective of this study was to determine the demographic, socioeconomic and personal 
predictors associated with people’s level of agreement to whether they think that second hand 
smoking is a risk factor for MS. Based on the results of this research it was evident that 
demographic factors were associated with people’s perceptions of whether second hand smoking 
is a risk factor for MS. As a secondary objective we explored whether this perception varied 
based on the province of residence to find out if there is a macro level effect. The complete case 
analysis indicated that 1.9% of the variability in responses in the dependent variable was 
explained by province in which the person resided. One of the reasons for this variability could 
be due to taxes on cigarettes and the tax hike that occurred in certain provinces over the years.15 
Another reason for this variability could be due to effects of stop-smoking campaigns in the 
provinces and the frequency in which messages about the harms of second hand smoking are 
shown in advertisements.  
 
In this study, 39% of people agreed that second hand smoke causes MS while 61% of people 
disagreed to second hand smoke causing MS.  The low prevalence of people in Canada who 
agree to second hand smoke being a risk factor for MS development shows the lack of awareness 
of MS risk factor. Males were more likely to agree that second hand smoke causes MS in 
comparison to females. The prevalence of smoking among males globally is 4.4 times greater in 
comparison to females.16 However an interaction effect was seen whereby male non-smokers 
were more likely to agree that passive smoke exposure causes MS as opposed to male smokers. 
Similar interaction effect was found for female non-smokers compared to female smokers. 
Therefore smoking status plays a role in people’s perceptions since smokers were more likely to 
disagree to harmful effects of passive smoking as oppose to non-smokers.  
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Having household members who did not smoke was associated with greater odds of people 
agreeing that passive smoking is dangerous. This finding was similar to a study conducted in 
Oregon whereby households with non-smokers or with at least one smokers, fully banning 
household smoking was associated with a greater awareness of the harms of smoke exposure.17 
This shows the importance of banning smoking in households and it’s impact on people’s 
perceptions.  
Age was a contributing factor in opinions for second hand smoke and MS development in that 
older individuals were more likely to agree that second hand smoke causes MS as opposed to 
younger people when looking at comparisons between age categories. A study done on the 
prevalence of passive smoking found that a higher prevalence of passive smoking was evident in 
the older population as opposed to the younger population.18 This suggests that older individuals 
may have experience with the harms of second hand smoke exposure and may be aware of the 
harms associated with it as opposed to the younger generation. With age comes more life 
experiences in terms of having friends or family members who have gone through problems with 
MS. Therefore they would have a better understanding of risk factors of primary and secondary 
smoking and its effect on health.  In addition to this older individuals may be more inclined to 
quit smoking or reduce the harms of passive exposure based on advice received from clinicians 
so that they can improve their quality of life.19 
 
Individuals who had greater levels of education such as high school degree or greater were less 
likely to agree to second hand smoke exposure being a risk factor for MS. These findings were 
consistent with a study that investigated the sociodemographic characteristics and second hand 
smoke exposure among women.20 In this study it was found that that women who had lower 
levels of education were more likely to be exposed to second hand smoke exposure.20 The 
findings from this study suggest that having higher levels of education doesn’t necessarily mean 
that a person has more awareness and that perception of risk factors may be due to personal 
experiences.  
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This study had many strengths. This was the first multilevel study that assessed people’s 
knowledge on whether they think that second hand smoking is a risk factor for MS development.  
Secondly the model correctly classified 70% of people on their perceptions of whether second 
hand smoke causes MS indicating a good model fit. The sample used was representative of the 
Canadian population since the major provinces were surveyed. Some of the limitations of this 
study is response bias. Survey respondents may assume that second hand smoke exposure may 
causes MS because of the way in which the question was asked and might answer in a desirable 
manner. Non-response bias is also present in this survey due to the high number of missing 
observations. Since this was a cross sectional study, a cause and effect relationship cannot be 
assumed. Another limitation was the high number of smokers in the survey which could have 
biased the results of the study, since smokers are more likely to disagree that smoking is 
detrimental to health, they would be more inclined to disagree to the question of whether second 
hand smoke exposure could increase risk of MS.  
 
Limitations also exist with regards to the survey question. Since only one survey question was 
asked and it didn’t have a definition of what MS was, there could be problems with people 
understanding the health condition before answering the question. Another limitation is that the 
survey is more than 10 years old, the knowledge of second hand smoking has increased and the 
levels of smoking in the general population has declined, therefore the results of this study and 
the recommendations made may differ in today’s population. In addition to this, the survey was 
conducted through telephone interviews which may lead to higher number of non-responses if 
individuals are not available during the time the call was placed.  
Public health awareness about the risks of second hand smoke exposure is needed. There have 
been two studies that have shown the impact of second hand smoke exposure and how it 
increases the risk of developing MS among children and adults.3,5 In order to reduce the exposure 
in public places, legislative bans need to be more restrictive in terms of specifying where people 
can’t smoke.  
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Public smoking bans in Canada has been effective in reducing the prevalence of smoking and 
have been effective in reducing rates of illnesses such as acute myocardial infection in 
Saskatoon.21–23  However, in terms of MS, not many people are aware that second hand smoke 
exposure can trigger relapses in MS, therefore patient and public education is important. One 
way to educate people about second hand smoking and MS is through advertisements on 
television or on buses.  
 
Advertisements about the harms of cigarette smoking and it’s effect on lung cancer or on alcohol 
use and impaired driving have been effective in raising awareness in these two areas and can also 
be effective for diseases such as MS.24,25 Creating stop smoking campaigns which includes 
messages about harmful effects of second hand smoking and it effects on neurological conditions 
such as MS would also be effective in reducing smoking and second hand smoking. 
 
Patient and family education about the risk factors for MS is important so they can be better 
informed as to what triggers to avoid. Since second hand smoke exposure could be avoided, 
physicians should communicate to caregivers about risk factors and give out educational 
materials such as pamphlets or books about MS. A study on the effect of a website that provides 
in depth information about beta interferon therapy found it to be useful for many patients.26 
Websites such as this could show information regarding risk factors such as second hand smoke 
exposure and its effect on MS. Another study by Kopke et al. (2014) found that patients who 
were in the educational program showed more risk knowledge which was beneficial for 
immunotherapy uptake. Educational programs on second hand smoke exposure and its impact on 
people living with MS could be beneficial to the public.27    
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Since sociodemographic factors were associated with people’s perceptions about second hand 
smoke exposure and MS, educational programs that raise awareness on this topic need to be 
created. In addition to this stop smoking campaigns need to incorporate messages about the 
various health problems that second hand smoke exposure could cause in children as well as in 
adults. Lung cancer, chronic obstructive pulmonary disease and heart disease are the main 
problems which are normally advertised as health problems associated with second hand 
smoking, other illness such as MS are left out and should be incorporated into stop smoking 
campaign messages.   
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CHAPTER 4: PSYCHOSOCIAL FACTORS ASSOCIATED WITH PAIN IN PEOPLE 
WITH MS 
 
Abstract  
Objective: Pain is a common problem in MS.  Risk factors associated with pain may include 
individual’s cognitive thinking process, emotional and behavioural response to pain and amount 
of social support. The primary objective of this study was to determine the association between 
amount of social support and its association with odds of pain among individuals with MS.  
Methods: The Survey on Living with Neurological Conditions in Canada (SLNCC) 2011-2012 
linked to the Canadian Community Health Survey (CCHS) 2010-2011 was used to carry out a 
logistic regression model for this analysis. The factors that were assessed were psychological 
factors, problems with sleeping, self-perceived general health, self-perceived level of stress , 
number of years living with MS, as well as social factors (someone to confide/talk to, someone 
to do something enjoyable, someone to take you to the doctor and someone to help you in an 
emergency). The outcome variable was presence of pain.  
Results: The amount of social support was found to be significant in that individuals who had 3 
or less types of social support were 3.02 times more likely (95% CI 1.06 to 8.59) to be in pain as 
opposed to individuals who had 4 types of support. 
Conclusion: The results indicate that caregivers may not be available to help with all type of 
activities, therefore home care services are very important. Reducing cost of home care services 
would be beneficial for people living with MS. 
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4.1 Introduction 
 
Pain is a common problem in people living with MS.1 The prevalence of pain in MS patients is 
50%, and 75% of patients report having pain within one month of their assessment.2 The 
presence of pain among patients with MS is associated with increasing age, the longer duration 
of their illness, depression and increased functional impairment and fatigue.3 Pain causes 
changes to occur in the central nervous system (CNS) and affects the emotional processing area 
of the brain.4 When there is damage to the peripheral or CNS, neuropathic pain occurs. Pain 
caused by MS can be explained by cognitive behavioural model which suggests that there are 
both disease and non-disease factors that trigger pain.5  
 
In MS, pain may be headaches, back pain, neuropathic pain and or spasms.6 Non-disease factors 
associated with pain include the individual’s cognitive thinking process, emotional and 
behavioural response to pain and amount of social support. Biopsychosocial model of pain 
recognizes that psychological, social and environmental factors play a role in pain.7 Figure 4.1 
shows the biopsychosocial model of pain. Earlier models of pain looked at the role of social 
support and emphasized the importance of a transactional model where pain causes a problem 
and it effects mood or behaviour which then leads to more support from others.8 However this 
model now has been further explored and scientists believe that physical pain is connected to 
social psychological pain.8  
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Figure 4.1: Biopsychosocial model of pain recognizes that psychological, social and 
environmental factors play a role in pain. Adapted from (Gatchel et al.,2007).7 
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Several studies have stated that the effect of chronic pain in MS patients is linked to depression 
and is mediated by fatigue, anxiety and sleep.2,9–11 Since coping with MS is difficult, not having 
the support one needs could impact the emotional well-being of MS patients and exacerbate 
health problems.3,12 This could then lead to a domino effect where emotional stress could impact 
sleep conditions and increase pain levels. Some studies that have looked at the association 
between social support as a predictor of mental health among MS patients found that social 
support made a significant contribution to the mental health dimension of their quality of life.13,14  
 
Social support helps in three areas: the first is it provides emotional support such as love and 
affection, the second is instrumental support such as lending a helping hand to someone and the 
third is informational support such as from a physician or nurse.15 Learning to cope with the 
illness is also important in reducing disease burden. There are two types of coping strategies such 
as problem focused coping and emotion focused coping.16,17 Problem focused coping involves 
ways to change the problem that one is dealing with while emotion focused coping is related to 
managing the emotional distress of the situation. Each coping strategy is dependent on the person 
as well as the situation that they are dealing with.17 Social support is an important aspect of 
coping and whether lacking in one type of social support could lead to pain is an understudied 
area.  
 
In a study done on the psychological factors associated with chronic pain in people living with 
disabilities found that the perception of social support was associated with less pain and better 
psychological functioning. 18 Several studies have also shown that higher levels of social support 
are associated with higher levels of health related quality of life and lower levels of depression. 
13,14,19,20   There have been few studies that have investigated the risk factors associated with pain 
and the emotional well-being of people living with MS. The majority of studies have focused on 
a single category of social support.  The main objective of this study is to determine the 
association between amount of social support and it’s association with odds of pain among 
individuals with MS. The second objective of this study is to determine if there is an interaction 
between psychological factors and amount of support on pain.  
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Figure 4. 2: Pain Model. This diagram shows the variables which are considered in the model 
building process for pain. 
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4.2 Methods 
 
4.2.1 Data Source  
 
The Survey on Living with Neurological Conditions in Canada (SLNCC) 2011-2012 linked to 
the Canadian Community Health Survey (CCHS) 2010-2011 was used for this analysis.21 The 
SLNCC is a cross sectional survey that collected information on Canadian’s experiences of 
living with chronic neurological conditions.21 There were 18 neurological conditions which were 
included in the 2010 and 2011 Canadian Community Health Surveys.21 The sample surveyed for 
the SLNCC survey were drawn from all CCHS respondents and household members who were 
15 years of age and older living in the provinces being surveyed and who had one of the 18 
neurological conditions.21   
 
4.2.2 Variables assessed  
Individuals 15 years and older were used in the analysis. The factors  that were assessed were 
psychological factor (mood disorder such as depression, bipolar disorder, mania or dysthymia), 
problems with sleeping, self-perceived general health (poor or fair health, good, very 
good/excellent health), self-perceived level of stress (not at all or not very stressful, a bit 
stressful, quite a bit to extremely stressful), number of years living with MS (less than 10 years, 
11 to 21 years, greater than 22 years), as well as social factors (someone to confide/talk to, 
someone to do something enjoyable, someone to take you to the doctor and someone to help you 
in an emergency). 
There were 4 types of support questions asked following the prompt “people sometimes look to 
others for companionship, assistance or other types of support”, “how often is each of the 
following kinds of support available to you if you need it?”.21 Following this statement, the 
respondent was asked  4 questions“…someone to confide in or talk to about yourself or your 
problems?”, the second question was “….someone to do something enjoyable with?”, the third 
was “…someone to take you to the doctor if you needed it?” and the fourth was “…someone to 
turn to help in an emergency?” the responses were “none of the time, a little of the time, some of 
the time, most of the time and all of the time”.21 
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 The outcomes were recoded as “none”, “little/some”, “most/all” in order to have enough number 
of observations in each category.21 These 4 questions and the responses were combined together 
to create one support variable (someone to confide/talk to, someone to do something enjoyable, 
someone to take you to the doctor and someone to help you in an emergency) and categorized as 
either having less than 4 types of support or the second category being having all 4 types of 
support. The outcome variable was pain health status for which there were 5 categories (no pain 
or discomfort, pain prevents no activities, pain prevents a few activities, pain prevents some 
activities and pain prevent most activities). These categories were collapsed to either presence or 
absence of pain.  
 
4.3 Analysis  
 
In order to take into account the survey design, replicate sampling weights along with 
bootstrapped variance estimation were used which were recommended by Statistics Canada.22 A 
set of (n=500) replicate weights were used in order to account for population estimates and non-
responses. For the SLNCC linked data set, the bootstrap replicates are the sub samples which 
were drawn in order to estimate the variance of the CCHS estimates. All analyses was conducted 
at the Research Data Centre at the University of Saskatchewan using STATA IC 15.23 Figure 4.2 
shows the model for this analysis. 
 
Univariate analysis using a p-value of 0.20 was used as a cut point for the entry of a variable for 
multivariate analysis. A logistic regression model was built using the backward method based on 
a p-value of 0.05. Variables that were not included in the model were tested as confounders 
based on whether the addition of the variable changed the other estimates in the model by more 
than 20%. Receiver operating curve and the goodness of fitness test was to determine model fit.  
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4.4 Results  
 
There was a total of 78,623 respondents in the survey. Majority of respondents, 42% were living 
with MS for 11 to 21 years while 35% were living with MS for less than 10 years. There were 
51% of individuals who reported pain while 49% reported no pain (Figure 4.3). Based on the 
univariate analysis, years living with MS, self-perceived general health, mood disorder, problem 
with sleep and amount of family support were significant in the model (table 4-1).  Stress was 
not significant in the univariate analysis and was not included in the multivariate analysis. 
Initially health and amount of family support were the significant variables in the final model. 
However after testing for confounders, all variables which were removed initially were found to 
change the parameter estimates of the final model by 20% and were included back into the 
model.  
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Percentage of people with pain vs no pain.  
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Table 4. 1: Descriptive statistics and univariate analysis of predictors associated with pain.  
 Variables  OR 95% CI P-value N 
Number of years 
living with MS 
 
 0.112* 
 
 
11 to 21 years 1.88 0.95-3.71 0.07 32696 
Greater than 22 
years 
1.85 0.90-3.82 0.10 
18055 
Less than 10 years  Ref   27872  
    
Self-rated general 
health 
  p<0.001*  
Poor/fair 6.46 3.13-
13.32 
p<0.001 
26444 
Good/excellent Ref   52179 
     
Mood disorder   0.120*  
Yes 1.93 0.84-4.40 0.12 16785 
No Ref   61837 
     
Problem with sleep   0.010*  
Yes 2.50 1.25-5.00 0.01 52903 
No Ref   25719 
     
Self-rated stress   0.389  
Not at all/not very Ref   33746 
A bit  1.29 0.64-2.62 0.47 21300 
Quite a bit to 
extreme 
1.83 0.77-4.33 0.17 
23577 
     
Amount of support 
from family or 
friends 
  0.028*  
<4 types of support 2.98 1.13-7.88 0.03 6592 
4 types of support 
(someone to 
confide/talk to, 
someone to do 
something 
enjoyable, someone 
to take to the 
doctor and 
someone to help in 
emergency) 
Ref   
72030 
*significance is based on p-value <0.20  
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From the results of the multivariate analysis, individuals who had poor/fair health were 5.86 
times more likely (95% CI 2.64 to 13.05) to have pain as opposed to individuals who had good 
health/excellent. The amount of social support was found to be significant in that individuals 
who had less than 4 types of social support were 3.02 times more likely (95% CI 1.06 to 8.59) to 
be in pain as opposed to individuals who had all 4 types of support (table 4.2). 
Table 4. 2: Multivariate analysis of predictors association with odds of pain in people with MS.  
 Variables   OR 95% CI p-value 
Number of years living with MS 
 
 0.15 
11 to 21 years 2.06 0.95-4.44 0.06 
greater than 22 years 1.71 0.78-3.73 0.18 
less than 10 years ref     
 
 
Self-rated general health 
 
 p<0.001
* 
Poor/fair 5.87 2.63-13.05 p<0.001 
Good/excellent ref  
 
    
Mood disorder 
 
 0.67 
Yes 1.17 0.56-2.409 0.67 
No ref  
 
    
Problem with sleep 
 
 0.33 
Yes 1.47 0.68-3.18 0.33 
No ref   
    
Amount of support from family or friends 
 
 0.04* 
<4 types of support 3.02 1.06-8.59 0.04 
4 types of support (someone to 
confide/talk to, someone to do something 
enjoyable, someone to take to the doctor 
and someone to help in emergency) 
ref  
 
*significance based on p-value of <0.05.  
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Interactions were tested between mood disorder and family support and between health condition 
and family support. Based on the univariate analysis, both interactions were found to be 
significant. However when included in the multivariate analysis there were not found to be 
significant. Therefore both interactions were not included in the final model. Table 4.2 shows the 
results of the final model. The area under the curve gave a value of 0.75 which indicated that this 
model was a good model and the goodness of fit test indicated a value of 0.94 which indicated 
that the model was significant. 
 
4.5 Discussion 
The results of the study indicate that all types of social support are needed for managing pain in 
MS patients.  Lacking in one types of support increases the odds of pain among individual’s with 
MS. Therefore having someone to talk to about problems that they may have, having someone to 
do something enjoyable with allow for a sense of belonging. One study on coping and 
psychological adjustment among people with MS found that people with MS were less likely to 
seek out social support.24 In another study done on investigating the needs of people with MS 
found that socio-environmental support such as household adaptation, better transport and 
rehousing was the category that was most frequently suggested.25   
 
Many people with MS who are in the later stages of MS cannot carry out activities of daily living 
need support from their family or friends, therefore the burden of caregivers is increased as 
disability progresses. This becomes a problem because the caregivers usually tend to be the 
spouse of the person with MS and all activities such as bathing or moving the person from 
wheelchair to bed cannot be carried out by a spouse. Therefore the person with MS may lack the 
support they need if they are financially unstable to hire help from an organization. In a study 
done by Akku (2010) on caregivers and their level of stress in taking care of someone with MS 
found that the major predictors of feeling overburdened were feeling hopelessness, conflicts in 
decision making, not having enough time for leisure activities and social isolation.26 In addition 
to this, some people with MS may have loss of mobility which increases pain when carrying out 
even the simplest of tasks. Therefore lacking in one type of support would increase pain.  
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A study that examined the impact of walking impairment in people with MS found that among 
the 1011 people with MS, 41% reported having difficulty walking, with 70% stating that walking 
was one of the most difficult aspect of having MS and 74% stated that it disrupted their activities 
of daily living.27 In addition to this, 39% of people with MS stated that they never or rarely 
discussed the problem they have about difficulty with walking to their family doctor.27  
 
However not all caregivers will seek the support they need. In a study done on caregivers of 
people with MS experience of support found that some caregivers tend to reject support from 
other family members or friends because they did not want to face the reality that someone they 
love had MS.28 In other cases, rejecting help was also associated with wanting more control of 
the situation.28 Other reasons for not asking for help was the caregivers thought that no one knew 
the care recipient well enough to take care of them and though it was their responsibility to do it 
themselves.28 Some caregivers were not satisfied with the support services since it did not meet 
the needs of the care recipient.28  
 
It is important for caregivers to seek support when needed and talk to their doctors about getting 
the proper services. Having support workers, visiting nurses, home maintenance services, 
workplace or vehicle modification can improve quality of life of both the person living with MS 
as well as their caregiver.29 The results of the study also indicate that having poor health is 
associated with increased odds of pain among individuals with MS. MS is a condition that occurs 
with other conditions such as migraine headaches, back pain, depression, spasms etc. Therefore 
those who have MS may be in more pain because of these conditions and may have been 
overlooked in the diagnosis or they may not seek help for their conditions.  
 
A similar study done on self-rated health and association with pain have found similar results.30  
Other studies have pointed to self-efficacy as a predictor for self-rated health.31 Self-efficacy is 
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the ability of someone to adjust to the condition they have which would allow them to cope more 
effectively.31 It is linked to self-esteem and how much control a person has.31 There are 4 ways 
to improve self-efficacy: 1) experience of accomplishing a behaviour; 2) vicarious learning or 
modelling the behaviour; 3) through encouragement or support from others; and 4) through 
physiological arousal such as anxiety which is connected to the behaviour.31 Other studies have 
also showed that self-efficacy is a significant predictor of self-reported physical, cognitive and 
social functioning in MS.32  
 
The strength of this study is that an association between lack of support for people living with 
MS and pain outcomes were determined, in addition to this, the study highlights the importance 
of having support in helping patients with MS and the need for more affordable home care 
services for people living with MS. One of the limitations of this study was that the type of MS 
was not available as a variable which could have helped in determining whether pain levels 
varied based on type of MS.  
 
The support variable question which was asked did not specify whether it was informal or formal 
support, however it can be assumed that the question is asking about informal support (from 
family or friends) since the question prompt was “people sometimes look to others for 
companionship, assistance or other types of support”.21 However since the questions was not 
specific and didn’t given examples of the type of support, respondents may have answered based 
on formal support (organizations, agencies) they received.  
 
The role of caregivers is important to the well-being of people living with MS. Therefore it is 
important that they get the help they need in order to reduce burnout. The results of this research 
will inform clinicians about the importance of caregiver support and how to help their patients 
seek out quality services that can help them with their needs. An example of resources that 
clinicians can give to caregivers is caregiver educational materials. The MS society of Canada 
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has an information and resource page on their website which provide webinars to caregivers, 
peer support group and caregiver guides.33  
 
The MS society of Canada also has resources to help with respite services which provide primary 
caregivers a break from their duties by providing them with a personal care worker to come in 
and help the patient.29 In addition to this self-efficacy is important when overcoming many 
illnesses and people with MS should seek help if they cannot cope with their illness. The results 
of this study will also inform health care organizations on ways to improve home care services 
for people with MS especially in lower income neighbourhoods or on reserves. 
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CHAPTER 5: USING COMPLEMENTARY/ALTERNATIVE TREATMENTS (CAMS) 
REDUCE ADHERENCE TO MS MEDICATION 
 
 
Abstract  
Objective: Appropriate use of prescribed medications are crucial to preventing relapses from 
occurring, however do to the side effects of many medications, many people turn to 
complementary and alternative medicine (CAM) treatments. The objective of this study was to 
examine the predictors associated with MS medication use. The two categories that were 
investigated were various alternative treatments as well as comorbid health conditions.  
 
Methods: The Survey on Living with Neurological Conditions in Canada (SLNCC) 2011 was 
used to carry out the analysis. The outcome variable was whether or not the individual used 
medication for MS during the course of their illness. Logistic regression model was used to carry 
out the analysis. 
 
Results: Individuals who did not take CAMs were more OR=5.44 95% CI (1.37-9.29) likely to 
use medication for MS as opposed to those who used CAMs. Having a mood disorder was 
associated with greater use of medications for MS while back problems were associated with 
lower odds of medication use. 
 
Conclusion: The use of complementary treatment is associated with lower odds of MS 
medication use. Efforts should be taken by health care practitioners to inform patients about the 
benefits of disease modifying medications and why it should never be substituted with other 
treatments. 
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5.1 Introduction 
 
Multiple sclerosis (MS) is a demyelinating diseases of the central nervous system which has no 
cure.1,2 However, there are a wide range of disease modifying treatments, primarily medications 
that have been effective in slowing down the disease and reducing relapses from occuring.3 The 
main drugs are Beta Interferons, Glatiramer Acetate, Mitoxantrone, Natalizumab, and 
Fingolimod that can shorten the duration of attacks, decrease the frequency and provide 
symptomatic relief.4  In addition, medications can reduce disease progression, lower the number 
of emergency department visits and in general improve overall quality of life. Medication use 
benefit the patient as well as the clinician, health care system and society as a whole.  
 
The importance of early treatment initiation in MS has been found in many studies.3,5,6 Patients 
who had started treatments later in the clinical course of the disease had a greater risk of reaching 
a level 4 on the Expanded Disability Status Scale (EDSS) which indicates significant disability. 
The hazard ratio was 1.07 (95% CI 1.05 to 1.10).5 Earlier treatments were associated with better 
clinical outcomes.5 However one of the main reasons patients stop taking medication is because 
medication for MS is not a cure and although it prevents relapses from occurring, patients still 
have a wide range of symptoms and side effects such as bladder dysfunction, chronic pain, 
cognitive decline as well as mobility problems.7 Disease modifying medications (DMTs) can 
help to slow down the progression of the disease but they cannot reverse the lesions that have 
already taken place.8  
 
DMTs may need to be stopped if there are serious adverse side effects that are life threatening.6 
Some side effects may occur such as with the drug fingolimod which increases the risk of 
opportunistic infections in patients and causes low lymphocyte count in peripheral blood.6 In 
order to reduce symptoms such as spasticity, antispastics such as baclofen, tizanidine, diazepam 
and clonazepam could be used, however there are adverse effects associated with this line of 
medication such as postural instability and vertigo.9  
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Up to now there hasn’t been many studies that have been conducted on whether using 
complementary/alternative treatments (CAMS), rehabilitation therapy or other conditions impact 
medication adherence in positive or negative way. Due to adverse side effects of medication use 
people often turn to complementary/alternative medicine treatments (CAMS) such as natural 
health products, herbs, homeopathic medicine, vitamins, acupuncture or exercise.10 Another type 
of auxiliary treatment is rehabilitation which is an understudied area whereby rehabilitation helps 
with walking or balance but whether rehabilitation impacts MS medication use has yet to be 
explored. Rehabilitation interventions has been considered beneficial in the earlier phases of MS. 
It is used to reduce symptoms and help improve the quality of life of people with MS.9  The most 
important aspect of rehabilitation is that patients can have various types of difficulties from 
physical, behavioural or cognitive but rehabilitation programs can help the patient by altering the 
treatment regimen in order to better serve the needs of the patient.9  
 
Having one or more conditions may also affect whether or not individuals take medication for 
MS. Chronic diseases may co-exist together because of chance or patients may be diagnosed 
with another disease because of frequent use of health care services.11,12 In other cases, diseases 
may co-exist together because of genetic susceptibility to immune disorders, environmental 
factors and independent factors such as age, obesity and diet.11,12 Diseases may co-exist together 
because they are a product of another undiagnosed disease.11  Psychiatric illnesses may influence 
medication use or may hinder it but studies are lacking in this area. Some studies have shown 
that psychiatric disorders such as depression and anxiety are common among individuals with 
MS.13–15 
 
Cognitive behavioural therapy has been shown to help patients cope with MS and improve 
overall quality of life. Majority of CBT’s focus on treating depression, however whether it 
reduces disease progression has yet to be studied. Other areas include mindfulness based 
interventions which were found to be effective in helping patients be aware of present 
experiences and reduce emotional distress.16 A review on mindfulness based interventions found 
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that stress could lead to disease progression for MS patients and that mindfulness could be used 
to accept the presence of the disease and to look for a better outcome on life.16  
There are a vast number of social behavioural models that have been found to be effective in 
helping patients adhere to medications.17  Models such as the health belief model, information 
motivation behavioural (IMB) skills model, situated IMB model of care Imitation and 
maintenance, social cognitive theory, self-regulations theory, theory of planned behaviour, 
protective motivation theory, trans theoretical model, chronic care model, self-management 
theory, Anderson behavioural model and ecological/socio-ecological framework/ model has been 
found to be effective for helping patients to change their behaviour.17  
 
For example the health belief model is commonly used to change ones behaviour with regards to 
compliance to medications. One of the main features of this model is that the patient has the 
choice and are able to decide what is best for their health.18 It is dependent on whether the patient 
thinks that they are at a risk for an illness, whether they think the health condition has 
consequences, whether there is a course of action for the illness and whether the benefits of 
taking the action outweigh the costs.18  There are six main concepts to the model which are 
perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action 
and self-efficacy.18  
 
In a study done by Kamran et al. (2014) to determine whether the health behaviour model was 
effective in helping patients adherence to hypertension medication, it was found that adhering to 
medication was low because patients perceived susceptibility, perceived severity and perceived 
benefits were inadequate and they had poor lifestyle factors.18 Therefore it was concluded that 
patients perceptions of medications needed to be improve and that proper education was 
important.18 The results of the study indicated that based on the health behaviour model when 
pieces of the model are missing, the model isn’t effective in changing the persons behaviour. 
Therefore an effective approach for behaviour change that takes into account the social and 
behavioural factors of the patient need to be determined for effective behaviour modification to 
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take place. The main objective of this study was to examine the individual level  predictors such 
as having chronic conditions has an effect on medication use as well as whether types of CAMs 
and auxiliary treatments were associated with medication use in people who have MS.  
 
5.2 Methods 
 
5.2.1 Data Source 
 
The Survey on Living with Neurological Conditions (SLNCC) was used to perform the analysis. 
The SLNCC was linked to the Canadian Community Health Survey (CCHS).19 The SLNCC is a 
cross sectional survey that collected information on Canadian’s experiences with chronic 
neurological conditions. This survey is a cross-sectional survey of a set of 18 neurological 
conditions. The sample for the SLNCC survey was drawn from the CCHS respondents and 
household members who were aged 15 years of age and older.19 These respondents had to have 
at least one of the following 18 neurological conditions listed. 19 Only individuals who had MS 
were included in the study (N=267). As recommended by Statistics Canada, in order to take into 
account the survey design, replicate sampling weights and bootstrapped variance estimation were 
used in the analysis.19 A set of (n=500) replicate weights were used in order to account for non-
responses. For the SLNCC linked data set, the bootstrap replicates are the sub samples that were 
drawn and used to estimate the variance of the CCHS estimates.20  
 
5.2.2 Variables assessed  
 
Demographic factors such as age, sex, income and education were assessed. Age was categorized 
as 22 to 30 years, 31-40, 41-50 and greater than 51 years. Income was categorized as 5,000-
39,999, 40,000-59, 9999, 60,000-89, 9999 and 90,000 and greater. Education was categorized as 
less than secondary school, secondary school or grater and some post-secondary school or 
greater. The type of treatment were assessed in the model were complementary/alternative 
medical treatments, rehabilitation therapy and counselling/psychotherapy. Mood disorder was 
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examined as the psychological factor in the model.  Individuals were asked whether they had 
mood disorder or anxiety disorder for which there were 2 responses either yes or no.  
Other chronic conditions that were tested for were back problems, arthritis, heart disease and 
blood pressure and the responses were either “yes” or “no”. The age of first diagnosis of MS was 
also used in the screening process and was categorized as 31 to 40, 41 to 50 and greater than 51 
years of age. The outcome variable was whether or not the individual with MS had taken 
medication to treat their MS with a binary response of “1= yes” and “0=no”.  
 
5.3 Analysis 
 
A logistic regression model analysis was carried out for this study in order to determine whether 
each of the predictors were associated with medication use. These predictors were selected based 
on previous theories on this topic. Figure 5-1 shows the hypothetical model for the analysis. 
Unadjusted and adjusted odds ratios with 95% CIs with p-values were computed. Univariate 
analysis was conducted using a (p <0.20). Manual backward selection was used to build the 
multivariable model based on (p<0.05). A complete case analysis was conducted in which only 
variables with complete values were used in the model and missing values were removed. 
Cofounders were tested in the final model and were retained if the addition of that variable 
changed the coefficients of the other variables by more than 20%.  All possible interactions were 
assessed and added to the model if they were significant at (p<0.05). The effectiveness of the 
final model was assessed using receiver-operating characteristics (ROC). The analysis was 
performed using STAT IC 15. 
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Figure 5. 1: Model for MS medication use.  
 
 
 
 
 
 
Demographic Factors
age
sex
income
education
Age first diagnosed with MS
CAM Treatments
Complementary medicine
Rehabilitation therapy
Counsellings services
Health conditions
Back problems
Mood disorder
Arthritis
Heart disease
Blood pressure
MS medication use
Yes or No
N=73,347
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5.4 Results 
 
There were 306 individuals diagnosed with MS in the Survey of Living with Neurological 
Conditions in Canada (SLNCC) 2011 and of those 267 were included in the analysis. The final 
sample consisted of 73,347 weighted observations. There were 49,770 individuals who used 
medication to treat MS and 23,577 individuals who didn’t use medication. Based on the 
weighted percentage, 50% of individuals with MS were those who were 51 years of age and 
older, 33% were those who were 41-50 years of age, 12% were those 31-40 years of age and 5% 
were 22-30 years of age. 75% of individuals with MS were females while 25% were males. 
Figure 5-2 shows the age categories. Figure 5.2 shows the age categories. Based on Figure 5.3 
the majority of respondents were in the lower income bracket of 5,000 to 39,999. In terms of 
education, the majority of respondents had some postsecondary education or more, however 
education was not significant not having an impact on whether a person used medication for MS 
(Figure 5.4).  In the final model age and sex were controlled for. Although 
counselling/psychotherapy services and rehabilitation were not significant in the univariate 
analysis, they were tested for in the final multivariate analysis based on (p<0.05).  
 
 
 
 
 
 
 
 
 
 
  
90 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 2: Number of people living with MS based on age categories.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 3: Percentage of people living with MS based on income categories.  
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Figure 5. 4: Education level of respondents with MS.  
 
Based on the univariate analysis (see table 5.1), individuals who had an income of 60,000 to 
89,999 were more likely to take medications as opposed to those who had an income of 5,000 to 
39,999 OR=5.63 95%CI (1.50-21.2). Individuals who had back problems as a co-morbid 
conditions with MS were less likely to take medication as opposed to those without back 
problems OR=0.38 95% CI (0.15-0.98). Individuals who had a mood disorder were more likely 
to take medication for MS as opposed to those who didn’t have a mood disorder OR=5.39 
95%CI (1.60-18.17). 
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Table 5.1: Univariate analysis for predictors associated with medication usage.  
Variables Odds Ratio P-value 95% CI N percentage 
Age  
 
0.80    
22-30 ref   3540 5 
31-40 2.96 0.41 0.23-38.7 9018 12 
41-50 3.21 0.33 0.31-33.1 24455 33 
greater 51 2.65 0.36 0.33-21.5 36335 50    
   
Sex 
 
0.20    
Female 1.97 0.20 0.693-5.61 55361 75 
Male  ref 
 
 17986 25 
      
Income 
 
0.07*    
5,000 to 39,999 ref 
 
 30133 41 
40,000-59,999 1.17 0.76 0.43-3.23 12658 17 
60,000-89,999 5.63 0.01 1.50-21.2 13302 18 
90,000 or greater 1.90 0.33 0.52-6.99 17255 24    
   
Education 
 
0.95    
Less than secondary school ref 
 
 7269 10 
Secondary school graduate  0.81 0.79 0.163-4.01 14134 19 
Some post-secondary education or greater 0.81 0.75 0.214-3.03 51944 71    
   
Back problems 
 
0.04*    
Yes 0.38 0.05 0.146-0.98 16905 23 
No  ref   56442 77 
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Variables Odds Ratio P-value 95% CI N percentage 
Mood disorder 
 
0.01*    
yes 5.39 0.01 1.60-18.17 12155 17 
no  ref   61192 83    
   
Arthritis 
 
0.23    
Yes 0.52 0.23 0.17-1.51 15286 21 
No  ref   58062 79    
   
Heart disease   0.91    
Yes 1.09 0.91 0.25-4.70 3226 4 
No  ref   70122 96    
   
Blood pressure 
 
0.94    
Yes 0.97 0.94 0.42-2.24 14888 20 
No  ref 
 
 58460 80    
   
Complementary medicine 
 
0.08*    
Yes 0.40 0.08 0.15-1.12 15405 21 
No  ref   57942 79    
   
Counselling services 
 
0.20    
Yes 2.74 0.20 0.58-12.9 15966 22 
No  ref 
 
 57381 78    
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Variables Odds Ratio P-value 95% CI N percentage 
      
 Rehabilitation therapy   0.25    
Yes 1.86 0.25 0.65-5.34 28013 38 
No  ref   45335 62 
      
Age first diagnosed with MS 
 
0.23    
<31 ref   21839 30 
31 to 40 1.70 0.37 0.53-5.40 26811 37 
41 to 50 2.02 0.28 0.56-7.28 16497 22 
Greater than 51 0.58 0.35 0.18-1.84 8201 11 
 
* shows significance at p-value of  <0.20 
Numbers were rounded either up or down due to weights and bootstrapping procedures.  
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Based on the multivariate analysis and cross comparison chart (see table 5-2 and 5-3) individuals 
who did not take complementary medicine treatment were more likely to take MS medication as 
opposed to those who used complementary/alternative medicine treatment OR=5.44 95% CI 
(1.37 -9.29). Individuals with a mood disorder were more likely to take MS medication as 
opposed to those who did not have a mood disorder OR=5.5 95% CI (1.18-25.7). Individuals 
with MS who had back problems were less likely to take MS medication than those who did not 
have back problems OR=0.32 95%CI (0.11-0.95). Interactions were not found to be significant 
and were not included in the final model. In the model diagnostics, the ROC curve showed that 
the logistic regression model correctly classified 75% of people who used MS medication 
indicating that the multivariate model was a good one. The goodness of fit statistics which shows 
whether the observed and expected observations for the final model are good fit gave a value of 
0.23 indicating good model fit.  
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Table 5. 2: Multivariate analysis of predictors associated with medication usage.  
Variables Odds Ratio 95 % CI P-value 
Age   0.745 
22-30 ref   
31-40 0.95 0.06-15.26 0.97 
41-50 2.22 0.21-23.29 0.51 
Greater than 51 2.15 0.25-18.28 0.45 
    
Sex    0.098 
Male ref   
Female 2.65 0.84 - 8.14 0.96 
    
Income   0.06 
Less than 39,999 (<5,000 to 39,999) ref   
40,000-59,999 1.32 0.30-5.89 0.71 
60,000-89,999 7.72 1.37-43.6 0.02 
90,000 or greater 4.03 1.15-14.1 0.03 
    
Health conditions    
Back problems, excluding scoliosis, fibromyalgia and arthritis 0.04* 
Yes 0.32 0.11-0.95 0.04 
No ref   
    
Mood disorder  0.03* 
Yes 5.49 1.18-25.7 0.03 
No ref   
    
Types of alternative medicine  
Complementary/alternative medicine 0.016* 
Yes 0.18 0.05 - 0.73 0.02 
No ref   
    
 Rehabilitation therapy 0.099 
Yes 3.17 0.80-12.51 0.09 
No ref   
    
Counselling or Psychotherapy services  0.42 
Yes 2.05 0.35-11.95 0.42 
 No ref   
 
* shows significance at p-value of <0.05  
 
  
97 
 
 
Table 5. 3: Comparisons of odds ratios based on significant variables from the multivariate 
analysis based on p-value of <0.05. 
Variables                          no vs yes OR 95% CI 
Complementary/alternative  medicine treatments           5.44 1.37-9.29 
Mood disorder                               0.18 0.04-0.85 
Back problems                               3.12 1.05-9.29 
 
 
 
5.5 Discussion 
 
This study aimed to show the predictors that were associated with medication use for MS among 
patients in Canada. Sociodemographic factors were not associated with medication use.  This 
finding is in agreement with a similar study that found sociodemographic differences were not a 
factor in differences between complementary medication use and MS medication use among 
individuals diagnosed with MS.21  In the multivariate analysis sociodemographic factors were 
not associated with medication use however in the univariate analysis, increased income was 
associated with greater likelihood of medication use.  
 
From the analysis it was evident that using complementary and  alternative treatments (CAMs)  
was associated with lower medication use and this was reported by many studies that were done 
on complementary medicine.22 Another study examining the frequency and characteristics of 
complementary and alternative medicine use among patients with MS found that 67.3% of 
patients were currently using one or more complementary and alternative treatments.21 The 
patients who used complementary treatments were more severely affected by MS than non-users 
and had a greater duration of the illness.  
 
Studies have reported that the most common reason for using (CAMs) was the desire by MS 
patients to use holistic health care which looked at treatments that recognized the mind, body and 
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spirit aspects and dissatisfaction with conventional medicines. The most frequent (CAMs) used 
were herbs followed by massages and acupuncture.22 similar studies have reported use of 
vitamins, essential fatty acids and minerals. 23 Complementary and alternative medicine (CAM) 
are used frequently by MS patients because they experience improvements in their symptoms.24  
 
In some cases, patients decided to use complementary medicine instead of using conventional 
treatments because of the side effects associated with medications and they believed that 
concentrating on getting rid of the stress and using acupuncture helped them feel better over the 
years.24 Another study indicated that a patient had worsening of their symptoms after using β-
interferons and had become disabled because of paralysis of arms, legs and blindness in one 
eye.24 Although doctors had stated that it was due to the progression of her disease, she decided 
to use CAM which consisted of dopamine, noradrenaline, acetylcholine and serotonin in addition 
to diet and supplements which improved her symptoms.24  
Homeopathic medicine were used by majority of patients with MS who used complementary 
medicine followed by acupuncture, healing, yoga and dietary supplements.25 Another reason for 
turning to CAM was the dissatisfaction with medical treatments with regards to lack of support 
from health care professionals and having lack of control on medications being prescribed.25  
Comorbid health conditions are common among individuals with MS. Mood disorders and back 
problems were found to be associated with whether or not a person who had MS were likely to 
take medication. Mood disorders consisted of major depressive disorder, dysthymic disorder, 
bipolar disorder, panic disorder, and generalized anxiety disorder.26 
 
The results of our study stated that individuals with mood disorder were at a greater odds of 
medication use. This is consistent with the study which researchers examined the effect of 
comorbidities on disease modifying therapy (DMT) use in MS in which patients with depression 
were 13% more likely to initiate DMT compared to those who did not have depression.27 One of 
the reasons for this could be that individuals with depression may have had more active MS as 
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opposed to those did not have depression and this could be a reason for initiating DMT 
treatment.28  
 
Depression has also been correlated with fatigue caused by MS.29,30 Fatigue is a problem that has 
been overlooked over the years but new studies indicate that 50-90% of patients report fatigue as 
one of the symptoms of MS and affects many aspects of the person’s life.31  The lifetime 
prevalence of depression in MS patients is 50%.32 Therefore physicians prescribe Modafinil 
which is a type of medication that is used to promote wakefulness and reduce fatigue.29 This 
could be one of the reasons for the increase use of MS medication use among individuals who 
have mood disorder since Modafinil could be one of the prescribed medications along with first 
line medications for MS. Patients who have both MS and mood disorder may be more inclined to 
take their medication in order to reduce their fatigue which they may believe is the cause of their 
mood disorder. Psychiatric onset in MS and whether early signs of psychiatric illness could help 
with diagnosing patients as having MS has also been studied. It has been suggested that 
psychiatric episodes may occur before MS onset.33 This could be an explanation for why patients 
who have mood disorder are more likely to use medications.  
 
Back problems are a common problem in patients with MS due to painful spasms. In order to 
reduce painful spasms caused by MS, patients turn to massage therapy or acupuncture. Our study 
indicated that those with back problems had a lower adherence to MS medication than those 
without back pain. One of the reasons for this is that disease modifying medications for MS 
don’t target pain. Therefore patients turn to CAM in order to help relieve the symptoms.  In a 
study done on why patients use CAM, it was found that CAM helped them relax, reduced tension 
and reduced pain in addition to improving overall quality of life.34 Another study indicated that 
pain is managed poorly in the treatment course of MS and many patients have turned to opioid 
medication, benzodiazepines, massage therapy, marijuana and hypnosis treatments.35 
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One of the problems with adhering to medication is that when many medications are prescribed, 
the patient may find it difficult to manage them all. One example of an effective model is the 
health behaviour model. However the effectiveness is not based on the model that one chooses, 
but is based on tailoring the model to suit the person’s needs based on the type of illness they 
have, operationalize the factors such that the factors that motivate the person are identified and 
then to use the model based on these changes.17 In a study done by Kaluer et al. (2008) on 
compliance, adherence and the treatment of MS, researchers state that a comprehensive model of 
treatment adherence should integrate patient, therapist, illness, treatments factors as well as the 
external factors from the social environment. Therefore interventions needs to be tailored to the 
specific deficits of the patient. The main goal for interventions is to encourage the patient to take 
responsibility for their treatment which is self-commitment to change.36 Having good 
communication between the patient and health care providers is important for better progress in 
treatment.  
 
This study had several strengths. This is the first study that examined the association associated 
with medication use and assessed different type of treatments such as CAMs as a risk factor. The 
study highlights the problems that many individuals with MS face which is desperation to find a 
treatment that works regardless of safety. It provides awareness to primary care providers about 
CAM use by patients so that they can direct patients to counselling services that can help patients 
cope with MS. The limitation of this study is that it was a cross sectional survey, therefore a 
cause and effect relationship cannot be determined. Since the variables for medication and 
complementary and alternative medicine did not have specific types of medications used, it was 
difficult to state what specifically each respondent used and how it affected their overall health. 
The results of this research indicate that individuals who did not use complementary treatment 
were more likely to adhere to medication. Having other health conditions such as back problem 
and mood disorder were associated with medication use.  
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It is important to create targeted medication education programs for patients in order to help 
them understand the advantages and disadvantages of medication use as well as the potential 
harms of complementary treatments use alone without medication. Health care professionals 
should also look at comorbidities that patients with MS have so that drug interactions don’t take 
place with prescribed medication and patients can have tailored treatment for their specific 
conditions.  
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CHAPTER 6: THE EFFECT OF EXERCISE, YOGA AND PHYSICAL THERAPY ON 
THE QUALITY OF LIFE OF PEOPLE WITH MULTIPLE SCLEROSIS: SYSTEMATIC 
REVIEW AND META-ANALYSIS. 
 
Article reproduced with permission. Published on-line as: Alphonsus, K. B., Su, Y., & D’Arcy, 
C. (2019). The effect of exercise, yoga and physiotherapy on the quality of life of people with 
multiple sclerosis: Systematic review and meta-analysis. Complementary Therapies in 
Medicine, 43, 188-195. 
https://www-sciencedirect-
com.cyber.usask.ca/science/article/pii/S0965229918310021?dgcid=author 
 I contributed to the entire study design, data collection, quality assessment, data analysis, data 
interpretation and manuscript writing. This chapter includes total standard mean difference of 
combined intervention scores which were excluded in the published study.  
 
Abstract  
Objectives: People living with MS have a poor quality of life (QOL) because of the symptoms 
caused by the disease and there are various types of treatments to manage the symptoms aside 
from medication.  
Methods: A systematic review with meta-analysis was conducted using PubMed Medline and 
Scopus from 1990 to 2017. Standard mean differences were computed.  
Results: Eighteen studies met the inclusion criteria for this meta-analysis. Aerobic exercise was 
effective in improving satisfaction with physical functioning, d=0.35 (95% CI=0.08 to 0.62), 
mental functioning d=0.42 (95% CI=0.11 to 0.72), and social functioning d=0.42 (95% CI=0.15 
to 0.69). Physiotherapy was also found to be effective for physical functioning d =0.50 (95% CI 
0.19 to 0.80), mental functioning d =0.44 (95% CI 0.14 to 0.75) and social functioning d =0.60 
(95% CI 0.21 to 0.90).  
Conclusion: These findings suggest that aerobic exercise and physiotherapy improves the 
satisfaction of MS patients with their physical, mental/emotional and social role functioning 
strengthening the need for this kind of complementary treatment to include as normal practice in 
the treatment of MS.
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6.1 Quality of Life and MS 
 
Multiple sclerosis (MS) is a chronic autoimmune disease.1 This disease affects the myelinated 
axons in the central nervous system leading to neurological deterioration over time.1 MS is more 
common among individuals of Northern European descent.2 It is usually diagnosed between the 
ages of 20 to 50 years of age.3 The disease causes a wide variety of symptoms including muscle 
weakness, fatigue, ataxia, impaired speech, vision impairment, cognitive dysfunction and 
paralysis.4   
 
Individuals with MS have consistently been shown to have lower quality of life (QOL) scores.5  
Improving the quality of life of MS patients has been recognized as important in secondary 
prevention of MS.6–8 Quality of life (QOL) scales ensure the satisfaction of individuals with their 
physical, mental and social wellbeing. Health related QOL is based on the perspectives of the 
individual and how they feel in the various areas of their life such as their physical, mental and 
social health and is usually measured using a variety of questionnaires.8  
 
Exercise training in general has been recognized as a useful intervention to alleviate some of the 
symptoms of MS.9–14  Endurance training, resistance training and combination of both15 are the 
main categories of exercise that have been investigated for their effectiveness with respect to MS 
in experimental studies. Meta-analysis studies that have investigated the possible association 
between exercise and quality of life among individuals with MS have focused on an overall 
quality of life score as opposed to investigating the different types of exercise methods and their 
impact on the various domains of quality of life.4,16,17  
 
Yoga, a form of flexibility exercise that involves spiritual practice, breathing exercises and 
meditation has been used as a therapeutic method. It has been shown to help relieve stress and 
anxiety among individuals with neuropsychiatric disorders, however the impact of it among 
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individuals with MS has not been systematically investigated across quality of life domains.18 
Esmonde and Long AF (2008) state that yoga is among the six most effective complementary 
therapies for managing MS patient’s symptoms. It has its therapeutic effects on QOL by improving 
many of MS symptoms, including weakness, fatigue, mental impairments and helps reduce 
persistent pain, reduce stress and help in reducing the symptoms of cancer and prevention of 
cardiovascular disease19–22 The different types of movements involved in yoga may improve 
quality of life by relieving spasticity, cognitive impairment and mental stress as well as increasing 
physical and motor functions.23  
 
Physiotherapy interventions includes various types such as education, consultation, therapeutic 
exercise, and cardiorespiratory techniques.24 Physiotherapy has been known to help in recovering 
from MS such as in balance and gait and  for improving walking dysfunction in persons with MS.25 
It has also been used to help with urinary incontinence which is a common symptom of people 
living with MS.26 However besides helping in balance and gait as well as in urinary incontinence, 
not much research has been done on the benefits of physiotherapy on individual domains of quality 
of life and whether there are more benefits to the mental and social domains.    
 
Although systematic reviews on interventions to alleviate symptoms of MS has been conducted, 
the comparative effectiveness of various types of interventions have not been systematically 
assessed nor have studies that have looked at the impact of these intervention on specific 
domains of quality of life been systematically investigated. What this review adds new to the 
literature in an investigation on the comparative effectiveness of various types of interventions 
such as aerobic exercise, anaerobic exercise, mixed exercise, yoga and physiotherapy on the 
overall quality of life of individuals diagnosed with MS as well as looking at their specific effect 
on MS patients’ physical, mental, and social quality of life domains.  
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6.2 Methods 
 
6.2.1 Data sources and searches 
 
We performed a comprehensive search using the databases PubMed/ Medline and Scopus using 
key words” multiple sclerosis" AND "exercise “OR "physical activity" OR "physical therapy 
“OR "aerobic" OR "anaerobic" OR "strength" OR "flexibility" OR "yoga" AND "quality of 
life"  from 1990 to 2017. We started from 1990 in order to get the maximum number of citations 
possible for this study.  The inclusion criteria were: 1) study must have either a randomized 
control design, pre-test post-test design, quasi experimental design or cross over design 2) should 
be testing the effectiveness of either exercise, physiotherapy or yoga interventions, and 3) should 
have a standard recognized QOL outcome measure including specific measures of the 
subdomains  physical functioning, mental/emotional functioning and social role functioning 
domains.  
 
Three researchers KA, YS and CD were involved with title and abstract screening and 
differences were resolved through discussions.  Articles that had comparisons between a 
complementary therapy and control where the control had an exercise component were included 
in the meta-analysis as a separate study. Thus a single study could have 2 types of treatment. We 
excluded articles that did not have a measures of quality of life domains or those that did not 
have cases and controls. Systematic reviews, literature reviews, meta-analysis and case studies 
were also excluded. PRISMA and Meta-analysis of Observations Studies in Epidemiology 
(MOOSE) guidelines were adhered to.27,28 The modified Pedro scale was used to assess study 
quality. 
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6.2.2 Effect sizes and statistical analysis 
 
Quality of life was categorized into 3 categories: a) physical, b) mental and c) social health. 
Articles that did not have these components were not included in the meta-analysis. For each 
quality of life category, pooled standard mean differences were calculated as well as mean 
differences based on the type of exercise or therapy such as aerobic, anaerobic, flexibility, mix of 
aerobic and anaerobic, yoga or physiotherapy. We computed standard mean difference using 
Cohen’s d for physical, mental and social health scores for each study.29 The standard mean 
difference was calculated based on the mean difference between the treatment and control group 
divided by the pooled standard deviation. For randomized controlled trials we used the difference 
between the treatment and control group and for pre-test post-test studies we used the post-test as 
the intervention and used pre-test as the control.  
 
The aggregated or pooled standard mean difference was computed using a random effects 
models where heterogeneity was found and weighted using the sample size for each study. 
Heterogeneity was evaluated using the DerSimonian and Laird  statistics.30 When 
heterogeneity was absent a fixed effect model was used. A standard mean difference (SMD) of 
0.20 indicated a small effect, SMD of 0.50 indicated a medium effect and an SMD of 0.80 or 
greater indicated a large effect.31 
 
 In order to assess publication bias, funnel plots and Forest Plot ’s test were used.32 The 
assessment of study quality was conducted using the modified Pedro scale which can be found in 
Appendix B. Sensitivity analysis was carried out in order to assess the impact of each study on 
the overall estimates. This was done by removing each study one at a time and by recalculating 
the standard mean difference. Meta-regression was used to assess heterogeneity and study 
quality. All analysis was conducted using STATA IC 13.  
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6.3 Results 
 
There were 1015 articles initially identified through database searches in PubMed/Medline and 
Scopus. After duplicate titles were removed 586 titles remained. Another 443 potential articles 
were removed after title review. After abstract review, full texts were reviewed for 84 articles 
and 18 articles were used in the analysis based on inclusion and exclusion criteria. Figure 1 
shows the process in selection of the articles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 1:PRISMA flow diagram for exercise, yoga and physical therapy on health related 
quality of life.   
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Table 6.1 shows the characteristics of the studies that were included in the meta-analysis. There 
were 4 different types of quantitative measures of quality of life: Medical Outcomes Survey 
Short Form-36, Multiple Sclerosis Quality of Life-54 Questionnaire (MSQOL-54), Multiple 
Sclerosis Quality of Life Inventory (MSQLI), Multiple Sclerosis Impact Scale-29 (MSIS-29) and 
World Health Organization Quality of Life BREF (WHOQOL-BREF).  The majority of studies 
included in the analysis were carried out in USA and Australia with the common instrument used 
for the analysis being SF-36 and MSQOL-54.  
 
In total there were 828 participants in the study. The majority of study designs used randomized 
controlled trials with some being pretest post-test and others being cross over design. Based on 
the modified Pedro scale, the majority of the studies ranges from 5 out of 9 to 8 out of 9 on the 
scale indicating good study quality. Appendix A shows assessment of studies based on the 
modified Pedro scale.   
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Table 6.1: Description of studies that were included in the meta-analysis. 
 
Author, Study 
year 
Country N Study 
design 
Instrument 
Used 
Participants and 
age 
Type of 
MS  
Main findings  
1 Ahmadi et al. 
2010 
Iran 10 RCT Multiple 
Sclerosis 
Quality of 
Life–54 
questionnaire 
(MSQOL-54) 
Women with a 
mean age of 
36.75 years 
Participant
s with MS 
Significant 
improvements 
shown on the 
physical function 
and physical health 
MSQOL-54 scores. 
Treadmill training 
improved balance 
and walking 
capacity, fatigue and 
quality of life 
(QOL) in people 
with mild to 
moderate MS.  
2 Cakit et al.  
2010 
Turkey 23 RCT Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Men and women 
between age of 25 
and 62 years of 
age. 
Participant
s with MS 
Significant 
improvements 
shown on the 
physical function 
and role physical 
functioning on the 
SF-36 scale.   
Cakit et al.  
2010 
Turkey 19 RCT Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Men and women 
between age of 25 
and 62 years of 
age. 
Participant
s with MS 
Significant 
improvements 
shown on the 
physical function 
SF-36 scale. 
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 Author, Study 
year 
Country N Study 
design 
Instrument 
Used 
Participants and 
age 
Type of 
MS  
Main findings  
3 Cohen et al. 
2017 
USA 14 Repeated 
measures 
Multiple 
Sclerosis 
Quality of Life 
Inventory 
(MSQLI), 
Men and women 
between the ages 
of 18 to 64. 
Participant
s with MS 
Significant 
improvements 
shown on the mental 
score of the MSQLI 
but not for physical 
score. 
4 Dodd et al. 2011 Australia 71 RCT World Health 
Organization 
Quality of Life 
BREF 
(WHOQOL-
BREF). 
Men and women 
with a mean  age 
of 47.7 ±10.8 for 
experimental 
group and mean 
of 50.4 ± 9.6 for 
control group. 
Relapsing 
Remitting 
MS  
Significant 
improvement on the 
physical health 
domain of the 
WHOQOL-BREF 
scale for relapsing 
remitting MS 
patients.  
5 Gobbi et al. 
2016 
Italy  8 Pretest post 
test 
Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Men and women 
between the ages 
of 35 and 59 
years of age 
Participant
s with MS 
Significant 
improvement shown 
on the role-physical 
and vitality HRQOL 
subscales. 
6 Husinga et al. 
2011 
USA 26 Pretest post 
test 
Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Men and women 
with a mean age 
of 45.5 ±10.5  
Participant
s with MS 
Significant 
improvements 
shown on the 
physical function 
and social function 
scores of SF-36 
scale. 
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 Author, Study 
year 
Country N Study 
design 
Instrument 
Used 
Participants and 
age 
Type of 
MS  
Main findings  
7 Jackson et al. 
2012 
USA 26 Single 
group 
repeated 
measures 
Multiple 
Sclerosis 
Quality of 
Life-54 
Questionnaire 
(MSQOL-54) 
Men and women 
between the ages 
of 28 to 62 years 
Participant
s with MS 
Significant 
improvements in 
gait speed  
8 Kargarfard et al. 
2012 
Iran 21 RCT Multiple 
Sclerosis 
Quality of 
Life-54 
Questionnaire 
(MSQOL-54) 
Women with a 
mean age of 
32.6± 8.0 
Relapsing 
Remitting 
MS  
Significant 
improvement shown 
on the physical and 
mental MSQOL-54 
scores. 
9 Kerling et al. 
2015 
Germany 18 RCT Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Males and 
females with a 
mean age of 40 
for patient group 
and 44 years for 
control group. 
Patient 
with MS 
(no 
specific 
type) 
Improvements were 
shown for the 
physical 
functioning, social 
functioning and 
mental health scores 
on the SF-36.  
Kerling et al. 
2015 
Germany 38 RCT Medical 
Outcomes 
Survey Short 
Form-36 (SF 
36) 
Males and 
females (mean 
age of 40 for 
patient group and 
44 years for 
control group) 
Patient 
with MS 
(no 
specific 
type) 
Improvements were 
shown for the 
physical 
functioning, social 
functioning and 
mental health scores 
on the SF-36. 
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 Author, Study 
year 
Country N Study 
design 
Instrument 
Used 
Participants and 
age 
Type of 
MS  
Main findings  
10 Mutluay et al. 
2008 
Turkey 43 RCT Multiple 
Sclerosis 
Quality of 
Life-54 
Questionnaire 
(MSQOL-54) 
Men and women 
between the age 
of 27-55 years 
Relapsing 
Remitting 
MS or 
progressiv
e type 
Significant 
improvements 
noticed in the in 
physical scores for 
MSQOL-54. 
11 Oken et al. 2004 USA 42 RCT Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Men and women 
with a mean of 
49.8 ± 7.4 
Participant
s with MS 
Improvement in 
fatigue was found 
after 6 months of 
doing yoga.   
 
Oken et al. 2004 USA 35 RCT Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Men and women 
with a mean of 
48.8 ± 10.4  
Participant
s with MS 
Improvement in 
fatigue was found 
after 6 months of 
doing aerobic 
exercise.   
12 Patti et al. 2002  UK 11
1 
RCT Medical 
Outcomes 
Survey Short 
Form-36 (SF 
36)  
Men and women 
with mean age of 
45.2 ±12.0 for 
treatment and 
46.1±6.0 for 
control  
Primary 
and 
secondary 
progressiv
e MS 
Significant 
improvements on 
physical 
functioning, and 
mental health 
functioning scores 
of the SF-36. 
         
  
  
 
       
1
1
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 Author, Study 
year 
Country N Study 
design 
Instrument 
Used 
Participants and 
age 
Type of 
MS  
Main findings  
13 Pilutti et al. 
2016 
USA 10 RCT Multiple 
Sclerosis 
Quality of 
Life-54 
Questionnaire 
(MSQOL-54) 
Men and women 
between the ages 
of 18 to 60. 
Progressiv
e MS 
Significant 
improvements on 
physical functioning 
and mental health 
functioning scores 
of the MSQOL-54 
questionnaire.   
14 Ray et al. 2013 USA  21 Quasi 
experimenta
l before 
after trial 
Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Men and women 
with a mean age 
of 50.9 ±5.7 for 
experimental 
group and 
56.2±8.8 years for 
control group. 
Participant
s with MS 
Significant changes 
were not found for 
physical functioning 
and social 
functioning scores 
on the SF-36 scale 
but was found for 
emotional being 
scores.  
15 Romberg et al. 
2005 
Finland 91 RCT Multiple 
Sclerosis 
Quality of 
Life-54 
Questionnaire 
(MSQOL-54) 
Men and women 
between the age 
of 30 and 55 
years of age 
Participant
s with MS 
Improvements were 
noticed for the 
social functioning 
score. 
16 Salgado et al. 
2013 
USA 22 Pretest post 
test 
Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Men and women 
with a mean age 
of 48.1±10.5 
Participant
s with MS 
Significant 
improvements in 
functional strength,  
         
  
  
 
       
1
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 Author, Study 
year 
Country N Study 
design 
Instrument 
Used 
Participants and 
age 
Type of 
MS  
Main findings  
17 Solari et al. 
1999 
Italy  54 RCT Medical 
Outcomes 
Survey Short 
Form-36 (SF-
36) 
Men and women 
between the age 
of 18 and 65 
years 
Primary 
progressiv
e, 
relapsing 
remitting 
or 
secondary 
progressiv
e 
Significant 
improvements 
noticed in the 
mental health 
component of the 
MSQOL-54 
questionnaire.   
18 Sutherland et al. 
2001 
Australia 22 RCT Multiple 
sclerosis 
quality of life 
instrument 
(MSQOL) 
Men and women 
with a mean age 
of 47.18 ±4.75 for 
exercise group 
and 45.45±5.05 
for control group 
Participant
s with MS  
Significant 
improvements in 
physical functioning 
score.  
 
* Some ages are reported in mean and standard deviation (mean±SD). 
* Participants with MS: anyone who had MS regardless of type.  
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6.3.1 The Effect of Aerobic, Anaerobic, Mixed Exercise, Yoga and Physiotherapy on 
Physical, Mental and Social Domains of Quality of Life  
 
The pooled analysis of aerobic, anaerobic, mixed exercise, yoga and physiotherapy on the 
physical quality of life are shown in Figure 6.2.  There were  physical (20), mental (16) and 
social health (11) articles  found and regardless of the type of exercise there was  an overall 
positive effect of exercise on physical health18,33–51 (d= 0.19, 95% CI=0.06 to 0.32, p=0.004, 
=15.2%), mental health18,33–36,39,40,44,47–51 (d= 0.39, 95% CI=0.13 to 0.65, p=0.003, =65.7%) 
and social health18,35,36,38,41,44,47,48,50,52 (d= 0.26, 95% CI=0.02 to 0.49, p=0.03, =42.9%). Figure 
6.3 shows the forest plot for pooled effects of all complementary therapies on the mental health 
quality of life domains.  Egger’s test and funnel plot indicated that there was no small study 
effect bias for physical, mental health and social health (p=0.18, p=0.06, p=0.99).  
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a)  
 
 
 
 
 
 
 
        
 
b) 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: a) The effect of all types of complementary therapy on the physical health of people 
living with MS.  b) Funnel plot with pseudo 95% confidence limits for all types of 
complementary therapy.   
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a) 
 
 
 
 
 
 
 
 
 
b)  
 
 
 
 
 
 
Figure 6.3:a) The effect of all types of complementary therapy on the mental health of people 
living with MS.  b) Funnel plot with pseudo 95% confidence limits for all types of 
complementary therapy.   
 
Effect of all types of complementary therapy on the mental quality of life 
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a)  
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
Figure 6.4: a) The effect of all types of complementary therapy on the social health of people 
living with MS.  b) Funnel plot with pseudo 95% confidence limits for all types of 
complementary therapy.   
 
Effect of all types of complementary and alternative therapy (CAM) on the 
social quality of life of people living with MS 
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6.3.2 Aerobic Exercise  
 
There were seven studies of aerobic exercise interventions (low to high intensity such as 
walking, cycling, running etc.) with physical QOL health scores,18,33,38,44,48–50 five studies which 
had mental health scores18,44,48–50 and seven studies with social health scores.18,33,38,44,48–50 
Aerobic exercise intervention studies showed that aerobic exercise had a small effect on physical 
health of MS patients. These studies reported a standard mean difference SMD of d=0.351 (95% 
CI=0.08 to 0.62, p=0.012, =48.1%). A funnel plot and Egger’s test showed no small study 
effect bias (p= 0.100). ). Figure 6-5 shows the forest and funnel plot for this analysis. 
 
a)         
 
 
 
 
 
 
 
 
 
 
 
Effect of aerobic exercise on the physical quality of life 
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 b)   
 
 
 
 
 
 
 
 
 
Figure 6.5: a) The effect of aerobic exercise on the physical health of people living with MS.  b) 
funnel plot with pseudo 95% confidence limits for aerobic exercise.   
 
A small effect found was found for the impact of aerobic exercise on mental health, d=0.417 
(95% CI=0.112 to 0.721, p=0.007, =54.2%). The funnel plot and Egger’s test showed no small 
study effect bias (p=0.315).   
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a)        
 
 
 
 
 
 
 
 
 
b)  
 
 
 
 
 
Figure 6.6: a) The effect of aerobic exercise on the mental health of people living with MS.  b) 
funnel plot with pseudo 95% confidence limits for aerobic exercise.   
Effect of aerobic exercise on the mental quality of life 
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Aerobic exercise also had a small effect on social health with an SMD of d=0.423 (95% CI=0.15 
to 0.69, p=0.002, =35.1%). Again the funnel plot and Egger’s test did not show a small study 
effect bias (p=0.851). These combined results clearly show that aerobic exercise has a significant 
impact on the physical, mental and social health of MS patients. Figure 7 shows the forest plot 
along with the corresponding funnel plots. 
 
a)       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
Figure 6.7: a) The effect of aerobic exercise on the social health of people living with MS.  b) 
Funnel plot with pseudo 95% confidence limits for aerobic exercise.   
Effect of aerobic exercise on the social quality of life 
Effect of physiotherapy on the physical quality of life 
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6.3.3 Anaerobic Exercise   
There were four anaerobic exercise studies that had physical health QOL scores 36,41,44,46, two 
studies reported mental health scores36,44 and two studies reported social health scores.41,44 
Anaerobic exercise in MS patient groups did not have a significant effect on either physical, 
mental or social health. The SMD scores were for physical health quality of life was d=-0.02 
(95% CI=-0.30 to 0.26 p=0.90, =0%), mental health: d=-0.10 (95% CI=-0.47 to 0.28, p=0.61, 
=61.5%) and social health: d=-0.18 (95% CI=-0.81 to 0.45, p=0.573). Funnel plots and 
Egger’s did not show any small study effect bias (p=0.94) for the physical QOL studies.   
 
6.3.4 Yoga 
Three studies examined the effect of yoga interventions on physical health of MS patients.18,37,45 
Yoga did not have a significant effect on physical health d=0.11 (95% CI=-0.26 to 0.48, p=0.57, 
=0%). A funnel plot and Egger’s test showed no small study effect bias for yoga on physical 
health (p= 0.247). The three studies that assessed the effect of yoga on mental health found no 
significant effect d=0.46 (95% CI=-0.24 to 1.17, p=0.19, =70.2%). A funnel plot and Egger’s 
test showed no small study effect bias (p=0.398).  The one yoga intervention study that reported 
social health scores found that there was no effect d=-0.28 (95% CI= -0.89 to 0.32, p=0.36).18 
 
6.3.5 Physiotherapy  
Three studies used physiotherapy as an intervention and reported on physical and mental health 
outcomes.34,42,43 Physiotherapy did have a significant medium effect on physical health d=0.50 
(95% CI=0.19 to 0.80 p=0.001, =0%). An Egger’s test and funnel plot showed no small study 
effects bias (p=0.945).  Similarly physiotherapy was found to have a significant effect on mental 
health outcomes d=0.44 (95% CI=0.14 to 0.75, p=0.004, =0%). Egger’s tests and funnel plot 
indicated that there was no small study effect bias for mental health (p=0.174). The one 
physiotherapy intervention study that reported social health scores found that physiotherapy had 
a medium to large effect d=0.60 (95% CI = 0.21 to 0.9, p=0.002).42 Figures 6-8 and 6-9 shows 
the forest and funnel plot for the analysis.  
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a)      
 
 
 
 
 
 
 
b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 8: a) The effect of physiotherapy on the physical health of people living with MS.  b) 
Funnel plot with pseudo 95% confidence limits for physiotherapy.   
 
Effect of physiotherapy on the physical quality of life 
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a) 
       
 
b)  
 
 
 
 
 
 
 
 
 
Figure 6. 9:a) The effect of physiotherapy on the mental health of people living with MS. b) 
Funnel plot with pseudo 95% confidence limits for physiotherapy.   
 
 
Effect of physiotherapy on the mental quality of life 
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6.3.6 Combination of exercises 
 
There were five studies of combination of exercise interventions with physical and mental health 
QOL scores 36,40,47,50,51 and three studies reporting social health scores.36,47,50 Combination of 
exercises has a combination of various types of aerobic, anaerobic and flexibility or strength 
training exercises. No significant effect was found for the combination exercises on physical 
health QOL; d=0.06 (95% CI=-0.21 to 0.32, p=0.66, =0%), mental health QOL: d=0.59 (95% 
CI=-0.15 to 1.33, p=0.12, =83.7), or social health QOL: d=0.07 (95% CI=-0.24 to 0.39, 
p=0.65, =4.1%). Funnel plots and Egger’s tests showed no small study effect bias for physical 
(p=0.08) and mental scores (p=0.14) but did show for social scores (p=0.01).  
Based on the sensitivity analysis, there was no significant change made to the combined results 
by any single study indicating that the results were reliable. Meta-regression did not find specific 
variables that caused heterogeneity, but there could be other factors associated with the 
heterogeneity present in the study such as methodological issues with randomization within 
individual studies. However random effect models were used when heterogeneity was present in 
our study. The study quality was assessed using the modified Pedro scale (Appendix B). Based 
on the scale, the studies ranged from 5 to 9 with the majority of the studies in the 9’s. This 
indicated that the majority of studies that were selected were of high quality.  
 
6.3.7 Summary of Results 
 
Table 2 summarizes the impact in terms of effect size of each treatment type on MS patients 
QOL domains. For all domains of QOL, aerobic exercise was found to have a small significant 
effect. Anaerobic exercise, combinations of exercises and yoga did not have a significant effect 
on QOL. Physiotherapy was found to be most effective for the physical, mental and social 
domains in comparison to other types of complementary treatments.   
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Table 6. 2:Effect size estimates for interventions based on domains of quality of life. 
Domains Type of Intervention No of studies Cohen’s d 95% CI p-value Effect 
Physical Aerobic 7 0.35 0.08-0.62 
 
0.01 Small effect  
Anaerobic 4 -0.02 -0.30-0.26 0.90 
 
Combined 5 0.06 -0.21-0.32 0.66 
 
Physiotherapy 3 0.50 0.19-0.80 p<0.001 Medium effect  
Yoga 3 0.11 -0.26-0.48 0.57 
 
All types of interventions 20 0.19 0.06-0.32 0.004 Small effect  
Mental  Aerobic 5 0.42 0.11-0.72 0.007 Small effect 
Anaerobic 2 -0.10 -0.47-0.28 0.61 
 
Combined 5 0.59 -0.15-1.33 0.12 
 
Physiotherapy 3 0.44 0.14-0.75 0.004 Small effect 
Yoga 3 0.46 -0.24-1.17 0.19 
 
All types of interventions 16 0.39 0.13-0.65 0.003 Small effect  
Social Aerobic 7 0.42 0.15-0.69 0.002 Small effect  
Anaerobic 2 -0.18 -0.81-0.45 0.57 
 
Combined 5 0.07 -0.24-0.39 0.65 
 
Physiotherapy 1 0.60 0.21-0.90 0.002 Medium to large effect 
Yoga 1 -0.28 -0.89-0.32 0.36 
 
All types of interventions 11 0.26 0.02-0.49 0.03 Small effect  
p<0.05 was used to identify significance 
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6.4 Discussions 
 
This systematic review and meta-analysis extends previous findings by showing aerobic exercise 
interventions in MS patients had a small effect size in improving patients physical mental and 
social QOL.  These results were consistent with a previous systematic review conducted on the 
effect of exercise as a treatment for multiple sclerosis that found aerobic exercise helps with 
depression.53 In general, studies have shown that aerobic exercise such as jogging, swimming, 
cycling, walking reduce anxiety and depression in individuals. It is hypothesized that exercise 
stimulates activity in the sympathetic nervous system (SMS) and activates the parasympathetic 
nervous system activity (PNS) which causes acetylcholine to be released resulting in a calming 
effect.54 
 
Studies have also shown that exercising in general allow for social interactions to take place and 
alleviate symptoms of social isolation.54 Our results are consistent with previous reviews where 
aerobic exercise have been found to improve physical health since it decreases fatigue and pain 
which are two main symptoms of MS.4,42,55 Endurance training was also found to help in 
improving aerobic capacity that MS patients lack.56 Recent literature has shown that endurance 
training for 3 months improved the quality of life of people living with MS.8  
 
Physiotherapy was also found to be beneficial in improving the physical and mental quality of 
life of people living with MS where it was found to have a medium effect on physical quality of 
life and small effect on mental health. This was consistent with a randomized controlled trial that 
assessed the effect of physiotherapy at home vs an outpatient vs no therapy program. Based on 
the study, it was found that physiotherapy improved mobility, subjective wellbeing and mood in 
people living with MS.57
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Smedal et al. (2006) investigated the benefits of physiotherapy for MS found similar results in 
that physiotherapy helped to improve balance and gait.58 In a summary of systematic reviews, 
incorporating therapeutic exercise into physiotherapy programs was found to be beneficial for 
people living with MS as well as other neurological conditions.59 Our pooled analysis of all types 
of complementary and alternative treatment (CAM) it was found that there was a small 
significant effect on improving the quality of life of people living with MS. Individuals who uses 
CAM reported that their overall stress was reduced and found improvements in their overall 
wellbeing. One of the main reasons for using CAM was the ineffectiveness of conventional 
medical treatments in not providing symptom relief and worsening of symptoms.60 In addition to 
this, the longer people use CAMs the less satisfied they were of conventional medicine.61 
 
 The strength of this systematic review and meta-analysis is that it looks at the effects of a variety 
of complementary therapies on specific quality of life domains and provides an estimate of the 
impact of those therapies on QOL in terms of effect size. A limitation of the analysis is that some 
studies could not be included in the meta-analysis because they either did not report physical, 
mental and social quality of life scores or were published in languages other than English. Some 
articles did not report mean and standard deviations needed to calculate SMD and where 
therefore excluded.  
 
The exclusion criteria also did not allow for the use of other types of quality of life scales such as 
fatigue impact scale which may have reduced the number of articles included in the meta-
analysis. There was also some heterogeneity that were found in some of the analysis which 
indicated variation in the degree of association between the type of intervention and its effect on 
the physical, mental and social health of individuals with MS. When heterogeneity was present a 
random effects model was used for the analysis. Publication bias that was present when assessing 
the effect of combination of therapies on social health was due to having only three studies in the 
analysis with one study being an outlier. Another limitation was some confidence intervals were 
wider, but this is due to the small sample sizes in the study.  
  
134 
 
 
 
This systematic review indicates that physical activity particularly aerobic exercise and 
physiotherapy had the greatest impact on physical, mental and social health as opposed to 
anaerobic, combination or yoga. This review provides strong evidence for the inclusion of 
aerobic exercise and physiotherapy programs as part of the regular treatment of patients with 
multiple sclerosis. Further studies need to be conducted in CAM treatments in terms of amount 
of treatment necessary in order for improvements to be noticed in physical, mental and social 
aspects of quality of life. The combination of CAM with traditional medications needs to be 
explored in order to determine the overall effectiveness of these treatments in relieving 
symptoms of MS.  
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CHAPTER 7: CONCLUSIONS 
 
This thesis covers several areas in MS research. The first area examined was to understand the 
public awareness of an important risk factor, second hand smoke exposure on MS development. 
The second was to understand how social factors play a role in pain experiences in people living 
with MS.  The third objective was to understand the factors associated with MS medication 
adherence. Lastly the thesis identified the various types of complementary treatments such as 
types of exercise on various domains of quality of life (physical, mental and social). This 
concluding chapter discusses the relevance of the findings. 
 
7.1 Summary of Findings 
The thesis explored various areas in MS research from prevention of risk factors such as second 
hand smoking to promotion of medication use and intake of aerobic exercise. The chapters each 
touch on difference aspects of MS from prevention to promotion.  The results presented in this 
thesis can help in the development of policies and inform health care professionals about the 
problems that many patients with MS face. Chapters 3 assessed awareness of second hand smoke 
exposure and it effect on MS while chapters 4, 5 and 6 looked at improving overall quality of 
life.  
  
Chapter 3 is the first study that examined the factors associated with Canadian’s public 
perceptions of second hand smoke exposure on MS development. The sociodemographic 
variables that were investigated were age, sex, marital status and education level. Other variables 
include number of people living in the household, whether other members of the household 
smoked, whether they were bothered by second hand smoke, smoking status, the number of 
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children in the household under the age of 18, frequency of breathing in second hand smoke and 
whether there were smoking restrictions in workplaces, restaurants or shopping malls. 
 
Through multilevel modelling the results of the study showed that the province of residence 
impacted the odds of a person agreeing to whether second hand smoke exposure could cause MS.  
The methodology used in this study used a multivariate multilevel mixed effects model which 
took into account the interaction effects of sex and smoking status and its effect on people’s 
perceptions based on the province in which they reside in Canada. The results of this study 
indicated that sex, age, education level, having household members smoke in the home and if the 
individual was bothered by second hand smoke exposure was associated with increased odds of 
people agreeing to second hand smoke exposure being a risk factor for MS development.  
 
Based on the multilevel mixed effects model, the province of residence of the respondent was 
also associated with perceptions about second hand smoke exposure on MS development with 
Newfoundland having (24%) and Ontario (23%) of people out of 1,639 people agreeing to the 
statement. This chapter explored the knowledge gap in MS and second hand smoke exposure and 
highlighted the need to strengthen the stop smoking campaign and to introduce messages about 
the harmful effects of second hand smoke exposure to the public.  
 
Chapter 4 explored the psychosocial factors associated with pain in people with MS. The Survey 
of Living with Neurological Conditions in Canada 2011 was used for this chapter. This chapter 
looked at health promotion and prevention. Pain is a problem with many conditions, however in 
MS it is one of the primary symptoms that many people face. Many studies explore pain from a 
biological standpoint, however the social aspect of pain has not been explored well in MS 
research. This chapter focused on social support and its association with pain in people with MS. 
The methodology used for the analysis used a logistic regression model to understand whether 
social factors were associated with pain among individuals with MS. This chapter drew attention 
to a hidden problem that many individuals with MS face which is having lack of support. Based 
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on the results of the study all types of social support are needed in order to reduce pain outcomes 
and that lacking in either one of the 4 (someone to take you to the doctor, someone to do 
something enjoyable with, someone to confide/talk to and someone to help in an emergency) is 
associated with increased probability of pain. Having someone to talk to or do something 
enjoyable allows for a sense of belonging which helps in promotion of positive mental health. 
Having someone to take you to the doctor if needed or for help in case of emergencies allows the 
person to reduce their stress because they know that there will be someone to help them when 
there is a medical emergency. When one of these supports are missing, the odds of pain 
increases.  
 
The results of this research indicate the importance of affordable access to health care services 
for individuals with MS. Not all individuals will have support from caregivers, therefore it is 
important to create programs that are affordable for individuals living with disabilities. The role 
of self-efficacy is also important since learning to cope with the problem at hand can help reduce 
pain and give a positive outlook to life. Therefore having social support is important for 
psychological health but at the same time is needed for help in case of emergencies.  
 
Chapter 5 investigated the factors associated with MS medication adherence using the Survey of 
Living with Neurological Conditions in Canada (SLNCC) 2010 to 2011 cycle. This is the first 
study that used a logistic regression model to understand the factors that promote medication use 
and factors that reduce medication use. Medication for MS is beneficial in order to stop relapses 
from occurring, however due to side effects of medication many people reduce the frequency of 
medication use or stop taking it altogether. Complementary/alternative treatment (CAM) such as 
exercise, herbal products, homeopathic medicine, vitamins, acupuncture, massage and meditation 
is beneficial when used with disease modifying MS medications, however when taken alone it 
can cause many problems to the overall health of the person with MS. This chapter showed the 
hidden factors that influence a person’s decision to take MS medications such as comorbid health 
conditions and the use of social behavioural models as a tool to help patients adhere to 
medications. 
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The analysis in chapter 6 which used systematic review and meta-analysis examined the effect of 
various types of interventions such as exercise (aerobic, anaerobic, mixed, yoga) and 
physiotherapy on the quality of life (physical, mental, social) of individuals diagnosed with MS. 
Overall quality of life was categorized into 3 categories: a) physical, b) mental and c) social 
health. Aerobic exercise such as treadmill training, elliptical exercise and aquatic exercise was 
beneficial for all domains of health. Physiotherapy was also found to be beneficial in improving 
the physical and mental quality of life of people living with MS. This chapter draws attention to 
patient’s quality of life and how each domain such as physical, mental and social health can be 
improved by doing aerobic exercise. The results of this study will reinforce physicians’ 
awareness of the benefits of exercise programs and how they could be incorporated into 
treatment regimens for patients. In addition to this, physiotherapy was also found to be beneficial 
for people living with MS and could also be used as a complementary treatment approach. 
However further studies in this area are needed in order to provide stronger evidence for these 
interventions.  
 
7.2 Practical Implications  
 
Based on the findings of this research more educational programs on the harmful effects of 
second hand smoking for people living with MS need to be created. In addition to this 
advertisements about second hand smoke exposure and its effect on MS need to be included on 
television or on public transportation services in order to increase public health awareness. The 
findings of this research also indicate a need for more affordable home care services for people 
living with MS especially for individuals who live in low income neighbourhoods.  
 
Primary care providers need to also direct caregivers and MS patients on nursing or home care 
services available in their area. In terms of medication used, low adherence is a problem that 
often goes unnoticed by primary care providers. The results of the chapter on medication 
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adherence highlight the desperation that people living with MS face as they turn to CAMs to 
reduce their symptoms. It also shows that poor health literacy and lack of knowledge in the area 
of MS medications among people living with MS is a problem. In order to increase medication 
adherence rates, patient education programs in hospitals need to be created that stress the harms 
of using CAMs and the benefits of medications. Primary care providers need to be aware of 
behavioural modification models that patients can use and should refer patients to counselling 
services that can help them cope with MS. The results of this dissertation also indicate that 
aerobic exercise such as walking, cycling, running and physiotherapy are beneficial for physical, 
mental and social health and should be incorporated into MS treatment regimens.   
 
7.3 Limitations 
 
The primary limitation of this study was the lack of data that was available on Multiple Sclerosis. 
Chapters 3, 4 and 5 relied on cross sectional surveys such as the Health Canada: Smoking Survey 
and the Survey on Living with Neurological Conditions in Canada (SLNCC), therefore a cause 
and effect relationship could not be stated. Since these surveys are self-reports they are prone to 
information bias and recall bias. In addition to this the cross sectional surveys were not repeated 
in consecutive years, therefore a cross year comparison could not be performed.  
 
There were limitations in using the Health Canada: Smoking Survey since it only surveyed 5 
provinces (Saskatchewan, Ontario, Newfoundland, Quebec and British Columbia) which left out 
many people in the population, thus reducing the sample size. There were limitations in the 
SLNCC data set with regards to the descriptions of the types of treatments that were used by 
people with MS. Types of medications were not mentioned clearly in the data set and specific 
complementary treatments were not clearly identified in the Statistics Canada Survey. Therefore 
it was difficult to distinguish between specific types of treatments. In addition to this there were 
some variables which were missing such as the types of MS that individuals had which could 
have given a clearer picture when carrying out the analysis. For the meta-analysis in Chapter 6 
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the limitations of the study was that the long term effects of each type of complementary 
treatments could not be determined since the immediate effect after the intervention was not 
measured.  
 
7.4 Future Work 
 
Based on the results of this thesis, future studies could look into assessing the level of knowledge 
that people have about risk factors for MS. This could help to understand how messages about 
risk factors could be spread to the public in order to increase awareness. Chapters 3 and 4 used 
the SLNCC data set since there weren’t any surveys that measured information about people 
living with MS in Canada. Since this was measured only once, it would be better if surveys were 
conducted every 2 years so that researchers could have access to MS data and a longitudinal 
study could be conducted. In addition to this surveys need to ask specific questions with regards 
to the type of MS the person has and the type of medication they used.  
 
The results of the study in Chapters 4 about lack of social support and having a greater 
probability of pain inform caregivers about the amount of support that a person with MS needs. 
This research can be built on by further delving into the area of how caregiver support can be 
managed stress free and whether programs need to be created in order to better educate 
caregivers on ways to help take care of their loved ones with MS.  
 
The results of Chapter 5 talk about using complementary treatment and its effect on medication 
use. Research on other factors associated with not complying to medication need to be examined 
such as the side effects of certain medications and what doctors can do to help patients. In 
addition patients and caregivers need to be better informed about the role of therapists in helping 
patients adhere to medications and how social behavioural models could be used as a tool to 
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manage medications better. Medication should be the primary line of treatment, however 
complementary treatments could also be used after consultation with the physician. 
 
The results of the study in chapter 6 examined how beneficial complementary treatments were in 
the various domains of quality of life. Aerobic exercise and physiotherapy was found to be more 
beneficial, however further research on the type of exercise regimens that is beneficial for the 
different types of MS need to be assessed. Research on whether targeted aerobic exercise 
programs are beneficial in the long run need to be examined as well.  
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APPENDIX A: Additional file for Chapter 6  
 Assessment of study quality using modified Pedro scale.  
Modified Pedro scale  
Study Eligibility 
Criteria 
Specified 
Random 
allocation of 
participants 
Allocation 
concealed 
Groups 
similar at 
baseline 
Assessors 
were 
blinded 
Outcome 
measure for 
more than 
85% of 
subjects 
Intention 
to treat 
Reporting of 
between group 
statistical 
comparison 
Point and 
variability for 
that measure 
reported 
Total 
score 
out of 
9 
Ahmadi et al. 2010  1 1 0 1 0 1 1 1 1 8 
Cakit et al.  2010 1 1 1 1 1 1 0 1 1 8 
Cohen et al.2017 1 0 0 1 0 1 0 1 1 5 
Dodd et al. 2011 1 1 1 1 1 1 0 1 1 8 
Gobbi et al. 2016 1 0 0 1 1 1 0 1 1 5 
Huisinga et al. 2011 1 0 0 1 0 1 0 1 1 5 
Jackson et al. 2012 1 0 0 1 0 1 0 1 1 5 
Kargarfard et al. 2012 1 1 1 1 1 1 1 1 1 9 
Kerling et al. 2015 1 1 1 1 0 1 1 1 1 8 
Mutluay et al. 2008 1 1 1 1 1 1 0 1 1 8 
Oken et al. 2004 1 1 1 1 1 0 0 1 1 7 
Patti et al. 2002 1 1 1 1 1 1 0 1 1 8 
Pilutti et al. 2016 1 1 1 1 0 1 0 1 1 7 
Ray et al. 2013 1 0 0 1 0 1 0 1 1 5 
Romberg et al. 2005 1 1 0 1 0 0 1 1 1 6 
Salgado et al. 2013 1 0 0 1 0 1 1 1 1 6 
Solari et al. 1999 1 1 1 1 1 1 1 1 1 9 
Sutherland et al. 2001 1 1 0 1 0 1 0 1 1 6 
 
